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Curcumin as a natural compound is made of various components including
protein, carbohydrate, and curcuminoid. Curcuminoid is made of curcumin,
desmethoxycurcumin and bis desmethoxycurcumin. Curcumin is used for the
treatment of cancer and inflammatory disorders, but it has some therapeutic
problems like poor bioavailability, poor efficacy, and chemical instability. To
overcome these problems, the objective of this study is (1) synthesis of pyrazole
curcumin analogs, (2) synthesis of triazole curcumin analogs, and (3) in-vitro study
of the anticancer activity of these curcumin analogs on head & neck, breast,
pancreatic and glioblastoma cancer cells.
During this part of my Ph.D. project, we have synthesized 9 pyrazole and 4
triazole curcumin analogs and studied their anticancer activity against CAL 27 and
UM-SCC-74A as head & neck cancer cell lines, MDA-MB-231 as breast cancer cell
line, HPAF as pancreatic cancer cell line, and MG118 as glioblastoma cancer cell
lines. We have studied the effect of these analogs on head & neck cancer cell lines
1
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by using cell proliferation assay and western blotting analysis. Compound 49
was shown the best anticancer activity on these cancer cell lines. Western blotting
analysis revealed that compounds 49, 81, and 77, showed anticancer activity. We
did MTS assay study on MDA-MB 231 as a human cancer cell line and the study
revealed that compounds 6 and 81 had good anticancer activity against these cancer
cell lines, while triazole analogs showed weak anticancer activity. We also used
MTS assay study to investigate the effect of curcumin analogs. Compounds 6 and
86 showed good anticancer activity against HPAF cell line. Cell Titer Glo-2 assay
study on MG118 cell line revealed that compounds 49, 51, and 80 had good
anticancer activity against glioblastoma cancer cell lines.
The expression of the CXCR4 gene leads to making a CXCR4 protein which
is a GPCR protein. Research showed that this protein is involved in different cancer
types. Overexpression of CXCR4 leads to cancer metastasis.
The objective of this study as the second part of my Ph.D. project is the discovery
of novel hit molecules targeting CXCR4. We did the virtual screening of 229358
natural product compounds. Based on the crystallography structure, we generated
the receptor file. FRED docking led to the identification of 500 hit compounds out
of 229358 compounds. 500 hit compounds were filtered based on several parameters
which led to the identification of 4 hit molecules. Root Mean Square Deviation study
has shown that two of these hit molecules stabilized the protein Structure. Moreover,
based on the Radius of the gyration study, three of these molecules maintain the
compactness of protein. The hydrogen bond study of these complexes showed that
two complexes made hydrogen bonds with targets. So, molecular dynamic analysis
by Gromacs led to the identification of 2 hit molecules for CXCR4 antagonist
activity.

3

Keywords: Curcumin, Cancers, In-vitro study

TABLE OF CONTENT
LIST OF FIGURES __________________________________________________ ⅷ
LIST OF SCHEMES __________________________________________________ ⅺ
LIST OF TABLES ___________________________________________________ ⅻ
LIST OF ABBREVIATION AND ACRONYMS __________________________ xiii
VITA

xiv

ACKNOWLEDGEMENT _____________________________________________ xv
PART ONE: DESIGN AND SYNTHESIS OF CURCUMIN ANALOGS FOR
ANTICANCER ACTIVITY _________________________________________ 1
1 INTRODUCTION________________________________________________ 2
1.1. Curcumin ________________________________________________________ 2
2 LITERATURE REVIEW __________________________________________ 4
2.1 Structural Characteristics ____________________________________________ 4
2.2 Curcumin Keto-Enol Tautomerism _____________________________________ 4
2.3 Extraction of Curcumin from Turmeric _________________________________ 6
2.4 Conventional Extraction Methods _____________________________________ 7
2.4.1 Soxhlet Extraction Method

7

2.4.2 Solvent Maceration Eethod

7

2.5 Modern Extraction Methods __________________________________________ 8
2.5.1Microwave-assisted Extraction (MAE)

8

2.5.2 Ultrasound-Assisted Extraction (UAE)

8

2.6 Chemical Synthesis of Curcumin ______________________________________ 9
2.6.1 Conventional Methods

9

2.6.2 Modern Methods

10

2.6.2.1 Microwave-Assisted Method

10
iii

2.6.2.2 Ultrasonic-Assisted Method

11

2.7 Drug Design Strategies _____________________________________________ 12
2.8 Natural Products __________________________________________________ 13
2.8.1 Introduction

13

2.9 Classification of Natural Products ____________________________________ 14
2.10 Role of Natural Products in the Drug Discovery and Development __________ 14
2.11 Pharmacological Activities of Curcumin ______________________________ 15
2.12 Antimicrobial Activity of Curcumin __________________________________ 16
2.12.1 Antibacterial Activity

16

2.12.2 Antifungal Activity

17

2.12.3 Antiprotozoal Activity

18

2.13 Anticancer Activity _______________________________________________ 19
2.13.1 Anti-Breast Cancer Activity

19

2.13.2 Anti-Lung Cancer Activity

20

2.13.3 Anti-Cervical Cancer Activity

21

2.13.4 Anti-Prostatic Cancer Activity

21

2.13.5 Anti-Pancreatic Cancer Activity

22

2.13.6 Anti-Colorectal Cancer Activity

23

2.14 Antioxidant Effect ________________________________________________ 23
2.15 Anti-Inflammatory Effect __________________________________________ 24
2.16 Antidiabetic Effect _______________________________________________ 25
2.17 Anti-Alzheimer Effect_____________________________________________ 25
2.18 Cancer Types Used for Study the Effect of Curcumin Analogs _____________ 26
2.18.1 Head & Neck Cancer

26

2.18.1.1 STAT

26

iv

2.18.1.2 pFAK

27

2.18.1.3 pERK1/2

27

2.18.1.4 pAKT

28

2.18.2 Glioblastoma

28

2.18.3 Breast Cancer

30

2.18.4 Pancreatic Cancer

30

2.19 Biological Study of Curcumin Analogs Effects _________________________ 32
2.19.1 Cell-Based Assay

32

2.19.2 MTT Assay

32

2.19.3 MTS Assay

33

2.19.4 Cell Titer Glo-2 Assay

33

2.19.5 Immuno-Blotting assay

34

2.20 Major Barriers of Curcumin's Clinical Efficacy _________________________ 35
2.21 Aim and Objectives _______________________________________________ 36
3 DESIGN OF THE STUDY ________________________________________ 37
3.1 Materials ________________________________________________________ 37
3.2 Instruments ______________________________________________________ 39
3.2.1 Instruments Used in the Synthesis ___________________________________ 39
3.2.2 Instruments and Methods Used for the Identification of Chemical Products __ 40
3.2.3 Instruments and Methods Used for the Effect of Curcumin Analogs on Cancer
Cell

41

3.3 Experimental Part _________________________________________________ 44
3.3.1 Separation of Curcuminoid ________________________________________ 44
3.3.2 Specific Aim 1 __________________________________________________ 45
3.3.3 Specific Aim 2 __________________________________________________ 60

v

3.3.4 Specific Aim 3 __________________________________________________ 69
3.3.4.1 Head & Neck Cancer ___________________________________________ 69
3.3.4.1.1 MTT Assay _________________________________________________ 69
3.3.4.1.2 Western Blot Analysis _________________________________________ 73
3.3.4.1.3 Molecular Docking ___________________________________________ 74
3.3.4.2 Human Breast Cancer Cells and Pancreatic Adenocarcinoma Cancer

76

3.3.4.3 Glioblastoma Cancer ____________________________________________ 77
4 RESULTS & DISCUSSSION _____________________________________ 78
4.1 Antitumor Activity ________________________________________________ 78
4.1.1 Analysis the Anticancer Activity of Crcumin Analogs on CAL 27 and UM-SCC74A head & Neck Cancer Cell Lines _____________________________________ 79
4.1.2 Analysis the Anticancer Activity of Curcumin Analogs on DA-MB-231 as Human
Breast Cancer Cell Line _______________________________________________ 80
4.1.3 Analysis the Anticancer Activity of Curcumin Analogs on HPAF as Pancreatic
Cancer Cell Line _____________________________________________________ 81
5 SUMMARY, CONCLUION AND RECOMMENDATIONS _____________ 82
PART TWO: DISCOVERY OF NOVEL HIT MOLECULES TARGETING
CXCR4 _________________________________________________________ 83
1 INTRODUCTION_______________________________________________ 83
1.1 CXCR _______________________________________________________ 84
2 LITERATURE REVIEW _________________________________________ 86
2.1 CXCR4 ______________________________________________________ 86
2.1.1 Receptor Grid Generation _________________________________________ 87
3 DESIGN OF THE STUDY ________________________________________ 89
3.1 Virtual Screening _________________________________________________ 89

vi

3.2 Virtual Screening Hit analysis _______________________________________ 91
3.3 Computational Details: _____________________________________________ 96
4 RESULT & DISCUSSION ________________________________________ 98
4.1 Structural Stability of CXCR4 Chemokine Receptor: _____________________ 98
4.2 Molecular Dynamic (MD) _________________________________________ 99
5 SUMMARY, CONCLUSIONS AND RECOMMENDATION __________ 101
APPENDIX ________________________________________________________ 102
REFERENCES

124

vii

LIST OF FIGURES
Figure 1-1 1. Curcumalonga

2

Figure 1-1 2 Chemical structure of curcumin

4

Figure 1-1 3 Curcumin keto-enol tautomerism

5

Figure 1-1 4 Keto-enol tautomerism of a curcumin analogue

5

Figure 1-1 5 NSAIDs with selective COX2 inhibition

13

Figure 1-1 6 Curcumin derivatives with an antibacterial activity

16

Figure 1-1 7 Curcumin derivatives with an antifungal activity

17

Figure 1-1 8 Curcumin derivatives with a potential anti-trichomoniasis activity

19

Figure 1-1 9 Curcumin analogues with a potential activity against breast cancer

20

Figure 1-1 10 Chemical structure of curcumin analogue JZ5

20

Figure 1-1 11 Chemical structure of curcumin analogue EF24

21

Figure 1-1 12 Curcumin analogues effective against prostatic cancer

22

Figure 1-1 13 Curcumin analogues with an anti-pancreatic cancer activity

22

Figure 1-1 14 Curcumin analogues effective against colorectal cancer

23

Figure 1-1 15 A series of curcumin derivatives with an antioxidant activity

24

Figure 1-1 16 Chemical structure of the curcumin analogue DM1

25

Figure 1-1 17 Chemical structure of the curcumin derivative named A4

25

Figure 1-1 18 Chemical instability of curcumin

35

Figure 1-3 1 TLC of curcuminoid

44

Figure 1-3 2 The graph of MTT results of anticancer activity of curcumin analogs on
UM-SCC-74A

71

Figure 1-3 3 the graph of MTT results of anticancer activity of curcumin analogs on
CAL-24

73

Figure 1-3 4 the western blotting analysis of curcumin analogs on UM-SCC-74 A 74

viii

Figure 1-3 5 docking study of SH-2 domain of STAT3 and compound 81

75

Figure 1-3 6 the effect of curcumin analogs on MDA-MB 231

76

Figure 1-3 7 the effect of curcumin analogs on HPAF

77

Figure 2-1 1. Chemokine receptor. A. Three pdb structures aligned (3ODU, 3OE0 and
4RWS). B. X-RAY crystal structure of Chemokine receptor (3ODU.PDB)

85

Figure 2-2 1. A. Binding of (6,6-dimethyl-5,6-dihydroimidazo[2,1 b][1,3] thiazol-3yl)methyl N,N'dicyclohexyl imido thiocarbamate in the active site of CXCR4 receptor.
B. Ligand binding interactions.

87

Figure 2-2 2. Receptor grid file prepared from 3ODU.PDB

88

Figure 2-3 1. Virtual screening flow chart.

90

Figure 2-3 2. Hits identified from Virtual screening (UNPD12783)

92

Figure 2-3 3. Hits identified from Virtual screening (UNPD102429)

93

Figure 2-3 4. Hits identified from Virtual screening (UNPD20535)

94

Figure 2-3 5. Hits identified from Virtual screening (UNPD93976)

95

Figure 2-3 6. The docked conformations of chemokine receptor with four natural
products.

97

Figure 2-4 1. The Chemokine complexes of (A) RMSD and (B) Rg plots.

99

Figure 2-4 2. The number of H-bonding interactions between chemokine and four
natural products.

99

Figure 1. H-NMR spectrum of compound 49

102

Figure 2. H-NMR spectrum of compound 50

103

Figure 3. H-NMR spectrum of compound 51

104

Figure 4. MS spectrum of compound 51

105

Figure 5. H-NMR spectrum of compound 57

106

Figure 6. MS spectrum of compound 57

107

ix

Figure 7. H-NMR spectrum of compound 58

108

Figure 8. MS spectrum of compound 58

109

Figure 9. H-NMR spectrum of compound 59

110

Figure 10. MS spectrum of compound 59

111

Figure 11. H-NMR spectrum of compound 60

112

Figure 12. MS spectrum of compound 60

113

Figure 13. H-NMR spectrum of compound 65

114

Figure 14. MS spectrum of compound 65

115

Figure 15. H-NMR spectrum of compound 68

116

Figure 16. MS spectrum of compound 68

117

Figure 17. H-NMR spectrum of compound 81

118

Figure 18. H-NMR spectrum of compound 86

119

Figure 19. MS spectrum of compound 77

120

Figure 20. MS spectrum of compound 78

121

Figure 21. MS spectrum of compound 79

122

Figure 22. MS spectrum of compound 80

123

x

LIST OF SCHEMES
Scheme 1-1 1 The number of H-bonding interactions between chemokine and four
natural products.

9

Scheme 1-1 2 Microwave assisted synthesis of curcumin analogue

10

Scheme 1-1 3 Synthesis of curcumin analogue by ultrasonic assisted method

11

Scheme 1-1 4 chemical conversion of MTT to formazan

32

Scheme 1-1 5 chemical conversion of MTS to formazan

33

Scheme 1-1 6 chemical conversion of Luciferin to oxyluciferin

34

Scheme 1-3 1 suggested mechanism of pyrazole curcumin analogs

48

Scheme 1-3 2 general scheme of synthesis of pyrazole curcumin analogs

51

Scheme 1-3 3 general scheme of synthesis of pyrazole curcumin analogs

62

Scheme 1-3 4 suggested mechanism of synthesis of propargyl curcumin analog

62

Scheme 1-3 5 general scheme of synthesis of triazole curcumin analogs

64

Scheme 1-3 6 suggested mechanism of synthesis of triazole curcumin analogs

64

Scheme 1-3 7 general reaction of synthesis of triazole curcumin analogs

66

xi

LIST OF TABLES
Table 1-3 1 The utilized solvents, reagents and chemicals with their suppliers

37

Table 1-3 2 Equipment’s utilized in this project with their companies and origins

40

Table 1-3 3 summery of attempted reactions

47

Table 1-3 4 chemical structure of pyrazole curcumin analogs

51

Table 1-3 5 summery of attempted reactions

61

Table 1-3 6 summery of attempted reactions

65

Table 1-3 7 chemical structure of triazole curcumin analogs

66

Table 1-3 8 MTT results of anti-cancer activity of curcumin analogs on UM-SCC74A

70

Table 1-3 9 MTT results of anticancer activity of curcumin analogs on CAL 24

72

xii

LIST OF ABBREVIATIONS AND ACRONYMS

AlCl3

Aluminum chloride

B2O3

Boron trioxide or Boric acid anhydride

CH2Cl2

Dichloromethane

CHCl3

Chloroform

CuSO4

Copper (II) sulfate

DMF
DMSO
DMSO-d6

N,N Dimethyl formamide
Dimethyl sulfoxide
Deuterated dimethyl sulfoxide

EtOAc

Ethyl acetate

EtOH

Ethanol

xiii

VITA

2010

Bachelor of Applied Chemistry
Kharazmi University
Tehran, Iran

2012

Master of Organic Chemistry
Iran University of Science and Technology
Tehran, Iran

2022

Graduate Research Assistant,
College of Pharmacy and
Health Science, Texas
Southern University

Major field

Pharmaceutical Sciences

xiv

ACKNOWLEDGEMENT
In the process of writing this dissertation, I have received a great deal of support
and assistance. I would like to take a moment to thank the many people who helped in
one way or another on this journey.
I want to express my deepest gratitude to my advisor Dr. Selvam Chelliah.
Thank you for your guidance and for believing in me throughout graduate school. Your
support, mentorship and enthusiasm has helped me to stay motivated through this
journey. I greatly appreciate you taking me into your lab and molding me into a more
independent scientist.
I would also like to express my deepest appreciation to my committee members
Dr. Rangana, Dr. Shivachar and Dr. Miranda for your guidance, scientific advice and
sharing your valuable expertise.
Finally, I am unable to find the words which can express my sincere and deep
gratitude to my family who sharing me in the transit through different work obstacles
and life problems; thus, this work is heartily dedicated to them.

xv

PART ONE
DESIGN AND SYNTHSIS OF CURCUMIN ANALOGS FOR ANTICANCER
ACTIVITY

CHAPTER ONE: INTRODUCTION
1.1.

Curcumin
Curcuminoid is the mainly biological compounds are extracted from the rhizome

of Curcuma longa. Curcuminoid is made of three chemical mixture including curcumin
which makes about 70 % of the curcuminoid. Desmethoxycurcumin and bisdesmethoxycurcumin are made 20% and 10% of curcuminoid, respectively[1].
Curcumin, also known as diferuloylmethane, has a yellow color and derived from the
rhizome of Curcuma longa (Figure 1-1 1) of the ginger family (Zingiberaceae)[2]. C.
longa is native to tropical South Asia and it grows in the temperatures between 20ºC
and 30ºC, and a considerable quantity of annual rainfall to grow[3].
Curcumin is extracted mainly from its richest and cheapest crude plant (C. longa).
However, it can be obtained from other crude plants likeCurcuma aromatica Salisb,
Curcuma amada Roxb, Curcuma zedoaria Rosc and Curcuma xanthorrhiza Roxb
which contain a relatively good quantity of curcumin[4].

Figure 1-1 1. Curcumalonga
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Curcumin, as turmeric, is using for a long time as a spice in India. Also, in India and
China it has been used for the treatment of many diseases such as diabetes, liver diseases,
cancer and rheumatoid diseases[5]. For the first time, in 1845, curcumin from C. longa
was isolated by Vogel and after about a half century, it was structurally characterized by
Milobedeska and his colleagues[6]. In 1913, curcumin was chemically synthesized by
Lampe and his colleague[7].
While it is freely soluble in some organic solvents such as dimethyl sulfoxide,
ethanol, methanol, and acetone, it is insoluble in water[8]. Curcumin has three tautomer,
one β-diketone form and two keto-enol forms. NMR studies show that β-diketone form
is not present in solution but only as a mixture of the equally present (due to symmetry)
keto-enol form. On the other hand studies shown that this tautomer is nots stable and it
degrades in the alkaline and acidic aqueous solution which leads to the poor oral
bioavailability of this natural medicine. Pure curcumin bioavailability on rat was %1.
Curcumin formulations were done for improving the curcumin bioavailability. The
highest reported bioavailability shown %46 improvement[9]. It is also light sensitive and
in the presence of light it degrades to several inactive byproducts[10].
In the structural point of view, curcumin is made of keto-enol moiety which is
hydrogen donor and acceptor which are important for making hydrogen bond with targets.
Curcumin also makes of two trans-double bonds and two benzyl groups which are
important for making hydrophobic interactions as well as π-π stacking interactions with
targets. It also has two hydroxyl and methoxy groups which are also hydrogen donor and
acceptor and are important to make hydrogen bonds with targets[11].

CHAPTER TWO: LITERATURE REVIEW
2.1

Structural characteristics
Curcumin chemical structure (Figure 1-1 2) has three chemical moieties including

2-methoxy-4-methylphenol, α,β- unsaturated bands, and keto-enole moiety. these
guaiacol rings are joined together by seven aliphatic carbons linker, the carbon chain
has an α,β-unsaturated β-diketone moiety[11], [12]. Curcumin is a symmetric molecule
with IUPAC name of (1E, 6E) 1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene3,5-dione. It has the chemical formula of C21H20O6, and the molecular weight of 368.38
g/mole[13], [14].

Figure 1-1 2 Chemical structure of curcumin

2.2

Curcumin keto-enol tautomerism
Curcumin is a tautomeric compound exists as two main tautomers, keto-enol form

and diketo form as shown in Figure 1-1 3. Curcumin is mainly found in the keto-enol
form (95%) which is chemically more stable than diketo form. When curcumin is
dissolved in a mixture of ethanol/ water, the two tautomers will be in a tautomeric
equilibrium. The addition of an excess water shifts the equilibrium toward the diketo
tautomer; while in a pure ethanol solvent, curcumin is mainly found in the keto-enol

4
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tautomer[15].

Figure 1-1 3 Curcumin keto-enol tautomerism
Curcumin tautomerism plays an important role in the biological activities of
curcumin. Curcumin is using for the treatment of Alzheimer’s disease. The main
pathological feature of Alzheimer’s disease is the formation of extracellular plaques
which consist of amyloid beta (Aβ) aggregates. Curcumin and its analogues exert their
anti- Alzheimer effect by the binding to these aggregates.
Research shown that the binding activity of the diketo form of curcumin analogues
(Figure 1-1 4) to Aβ aggregates was found to be much weaker than that of curcumin
analogues with a keto-enol form[16].

Figure 1-1 4 Keto-enol tautomerism of a curcumin analogue
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2.3

Extraction of curcumin from turmeric
Despite the two centuries that have elapsed since the initial extraction and

separation of curcumin from turmeric powder, some new and improved extraction
method for curcumin extraction were reported. The extraction methods could be
classified into the conventional methods (such as Soxhlet extraction and solvent
maceration) and modern methods (such as microwave-assisted extraction and
extraction by ultrasound-aided method)[17]. Since the extraction is the initial basic step
in qualitative and quantitative analysis of medicinal plant constituents, selection of the
most appropriate extraction method is important. Incomplete extraction process may
produce a poorly prepared extract and lead to an insufficient validation even when the
powerful chromatographic detection method is used[18].

7

2.4

Conventional extraction methods
There are many examples of the conventional methods which areapplied for

extracting curcumin from the crude plants like:
2.4.1

Soxhlet extraction method
This method is considered as a reference extraction method for evaluating the

efficacy of the other conventional and non-conventional extraction techniques. This
methos is more convenient for the extraction of curcumin when the extraction and
filtration performed in the dame step. Nonpolar to polar solvent like CHCl3, EtOAc,
MeOH and acetone are using for this method of extraction[19].
2.4.2

Solvent maceration method

Solvent maceration method is another traditional method for extracting of
curcumin. The rhizomes of crude plant were macerated via an organic solvent
followed by evaporation of solvent affording the turmeric oleoresin. Hexane, EtOAc,
acetone, MeOH and EtOH are commonly used for extracting curcumin with
preference to EtOH over the other organic solvents[20].
The major disadvantages of the aforementioned conventional extraction methods are
the consumption of a large amount of solvent, high temperature, long extraction time,
low yield and release of huge amount of solvent by evaporation into environment. All
these drawbacks restrict the use of conventional methods and provoke the researchers
to develop new advanced extraction techniques[21].

8

2.5

Modern extraction methods

Curcumin can be extracted from its natural sources by various modernmethods
such as:
2.5.1

Microwave-assisted extraction (MAE)
MAE is a relatively new technique used to accelerate the target compounds

extraction from their natural sources with a considerable efficiency and economy by
the microwave radiation. The theory of MAE is based on the migration of target
bioactive substances out of matrix through the solvent at the same time as the solvent
disperses into the sample matrix[22].
MAE has been considered as a green chemistry technique because it consumes a
low quantity of organic solvent. Other advantages of MAE include a high extraction
yield, small equipment size, less timeconsuming, faster heating of compounds, polar
and non-polar solvents can be used[23].
2.5.2

Ultrasound-assisted extraction (UAE)
UAE is a promising tool for the extraction of bioactive substances from their crude

plants. Ultrasonic waves facilitate the access of the extracting solvent inside the cells
by swelling and enlarging the pores found on the cell wall. Subsequently, the generated
microbubbles grow, implode and cause shock waves which in term result in cell wall
disruption. This action facilitates the release of constituents from inside the cells into
the surrounding solvent[24].

9

2.6

Chemical synthesis of curcumin

2.6.1 Conventional methods
One way for obtaining curcumin is to synthesize it by an aldol condensation
reaction. This reaction is a very important and widely used reaction in organic synthesis
for the formation of new C-C bond. Moreover, this reaction is using for the synthesis
of α,β-unsaturated carbonyl compounds that are extensively utilized in the commercial
production of pharmaceutical agents[25].
Aldol condensation reaction is doing under an acidic or basic condition.
Conventionally, this reaction is performed by the addition of a homogeneous basic
catalyst such as NaOH, KOH, magnesium oxide or zirconium dioxide supported on a
silica. The rationality behind the addition of homogeneous catalyst is to reduce the
reaction temperature and shorten the reaction time[26], [27].
The general scheme of curcumin synthesis under aldol condensation is shown in
scheme (1-1 1) this reaction was done in the presence of acetyl acetone and substituted
aromatic aldehydes like vanillin as building blocks[28].

Scheme 1-1 1 The number of H-bonding interactions between chemokine and four natural
products.
The selection of an appropriate solvent is the critical factor to produce adequate
solubility of the reactants, intermediates and products. DMF, EtOAc, acetonitrile, acetic
acid and toluene are considered a rational choice for curcumin synthesis. Although
curcumin can be obtained in a high yield, its chemical synthesis by a conventional

10

method is challenging since it consumes a long time to be completed, large quantity of
solvents to be employed and it is environmentally unfriendly[29].
2.6.2

Modern methods

2.6.2.1 Microwave-assisted method
Microwave irradiation is a green efficient method which commonly employed to
accelerate the chemical reactions either by using a less or no catalyst, recycling the
solvents and providing a better yield and purity than conventional synthetic
methods[30].
Scheme below shown the microwave reaction situation used for the synthesis of
curcumin analogs by condensing β-diketones with aromatic aldehydes. Alumina as
solid phase catalyst accelerated the reaction and reduced the reaction time twice as
compared with the other conventional methods[31].

Scheme 1-1 2 Microwave assisted synthesis of curcumin analogue
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2.6.2.2

Ultrasonic-assisted method

Ultrasound irradiation, also known as sonication, is an important technique in the
fields of synthetic organic chemistry and pharmaceutical industry. For many decades,
ultrasonic irradiation has become a well- known method for acceleration numerous
chemical reactions via various mechanisms such as the enhancement of dissolution,
acceleration of reaction rate, and renewing the surface of a solid reactant or catalyst[32].
Inayaha and his colleagues have synthesized several curcumin analogues via the
ultrasound irradiation. Although all the analogues had been synthesized with a high
purity, good yield, and short time reaction, the synthesis of the analogue shown in
scheme (1-1 3) and chemically named (2E,5E)-2,5-bis(4-(dimethylamino)benzylidene)
cyclopentanone has been considered as superior to the reminder analogues in terms of
purity and yield[33].

Scheme 1-1 3 Synthesis of curcumin analogue by ultrasonic assisted method
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2.7

Drug design strategies
Drug design is a creative method for designing new biologically active compounds

that are complementary in shape and charge to the biological target with which they
interact and bind to exert their biological effect[34]. After identification of the
significant binding group and pharmacophore of the lead compound, analogs that
contain the same pharmacophore can be synthesized. Different strategies have been
used to optimize the interaction between the drug and its target to gain a higher activity
and selectivity[35].
Ring variation is one of the most important strategies which can be applied to
optimize drug-target interactions resulting in the improvement of drug activity and
selectivity[36]. This strategy is extensively used for products possessing an aromatic or
heteroaromatic ring. The original ring is usually replaced with a range of other
heteroaromatic rings of different ring size and heteroatom positions. Recently,
accumulating evidence has suggested that the heterocyclic moieties are important
scaffolds in the development of new active agents with diverse potential activities[37].
Dup-697 is a lead molecule for the development of selective COX2 inhibitors.
Several non-steroidal anti-inflammatory agents (NSAIDs) withselective inhibition of
COX2 (Figure 1-1 5) have been synthesized by varying the central ring[38].
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Figure 1-1 5 NSAIDs with selective COX2 inhibition

2.8

Natural products

2.8.1 Introduction
Natural products have been extensively used as a folk medicine for a long time as
a trustable treatment of different diseases that affected human health[39]. Evidence
shown that using herbal medicinal plants dates back to 60,000 years ago[40].
Natural products can be defined as any chemical materials or substances that have
been gained or isolated from the living organisms[41]. Natural products shown
biological activity on many animals (especially mammals, insects, spiders

and

reptiles), marine organisms and microorganisms. Although these natural products
shown biological activity, sometimes the concentration of the active compound is low
or/and the purification is hard (especially when the substance of interest is unavailable
at adequate concentrations)[42], [43], [44].
Natural products can be obtained as an entire organism such as microorganism,
plant or animal, as a part from the organism such as animal organ, plant leaves or
flowers, or as a pure compound extracted from the organism such as coumarins,
alkaloids, flavonoids, steroids)[45].
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2.9

Classification of natural products
Natural products can be classified broadly into two basic classes called primary

and secondary metabolites. The primary metabolites include nucleic acids, lipids,
carbohydrates, proteins, and their precursors. These metabolites are essential for the
living of organism. On the other side, the secondary metabolites have occurred as key
intermediates in the primary metabolic pathways. Also, such metabolites may be found
temporarily throughout the cell cycle and may be specific for a particular group of
organisms[45], [46].
Secondary metabolites are usually exerted numerous functions such as the
protection against environmental stresses caused by pathogen, insect or herbivore
attacks. Furthermore, many secondary metabolites may have free radical scavenging
activity to aid the organism for encountering the oxidative conditions. In medicinal
chemistry, the term natural products is specifically referred to secondary metabolites
rather than to primary metabolites[47], [48].

2.10

Role of natural products in the drug discovery and development
Natural products play important roles in the treatment of several disorders. Ever

since ancient times, for the treatment of various disorders, people looked for drug un
nature. The beginnings of the medicinal plants’ use were instinctive, as is the case with
animals[49]. Because of the lack of information about the reason and concerning which
plant and how it could be used as a treatment, everything was based on experience.
Until the advent of iatrochemistry in 16th century, plants had been the source of
treatment and prophylaxis[50].
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The decrease efficacy of synthetic drugs and the limitation of suage of some of
them, made the usage of natural drug topics again. Although there are some advantages
of using medicinal plants as medicine for the treatment of various disorders, there are
some challenges like extraction, isolation, purification and chemically structure
modifications[51]. Despite all these impediments, natural products provide enormous
chemical diversity and highly extraordinary chemical structures greater than those
offered by the other currently available combinatorial and computational approaches
[52].
Most discovered drugs during the last four decades belong to the natural products
and their semisynthetic derivatives and less than 30% of the available drugs are made
synthetically. These statistics shown that although plenty research were done for the
development of synthetic drugs, natural products are still the major contributor in the
new drugs development[53].
Among the most extensively studied natural products, polyphenols shown
interesting biological activity like anti-inflammatory and antioxidant. Among these
phytochemicals, curcumin is one of the most investigated natural products[54].

2.11

Pharmacological activities of curcumin

A lot of study on curcumin as a main constituent of curcuminoid reported its
variety biological activities like acting as an antimicrobial[55], [56], anticancer[57],
[58], antioxidant[59], antidiabetic[60], [61], and anti-inflammatory[62], [63].
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2.12

Antimicrobial activity of curcumin

2.12.1

Antibacterial activity

Recently, the accumulative data revealed that curcumin shown a potential
antibacterial activity against both methicillin-sensitive S. aureus (MSSA) and
methicillin-resistant S. aureus MRSA[64], [65]. In addition to the curcumin potent
antibacterial activity alone, curcumin also provided a marked synergistic antibacterial
activity against S. aureus when concurrently combined with different antibiotics[66].
Beside its effect against S. aureus, curcumin has a remarkable activity against
Enterococcus faecalis, Bacillus, P. aeruginosa, E. coli, and K. pneumonia, also[13].
Singh et. al. reported two curcumin derivatives (A4 and B38) shown potent
antibacterial activities against S. aureus, P. aeruginosa, Enterococcus faecalis and E.
coli in a descending order (figure 1-1 6)[67].

Figure 1-1 6 Curcumin derivatives with an antibacterial activity
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2.12.2

Antifungal activity

Candida albicans as a derivative of curcumin considered as a major fungal
pathogen in humans and the most virulent pathogenic species of the genus Candida[68],
[69].
In addition to the high potency inhibitor activity of curcumin on the C. albicans
isolates[70], it has the capability of attenuating the C. albicans ability to resist
fluconazole when concomitantly combined with this azolebased antifungal drug[68].
Two curcumin derivatives chemically (L1 and L2) shown in figure 1-1 7 were
synthesized and tested for their antifungal activity against the following genera:
Aspergillus, Penicillium and Alternaria. Both analogues shown a potential inhibitory
effect on the growth of the test cultures with superiority contributed to L1 over the other
prepared derivative[71].

Figure 1-1 7 Curcumin derivatives with an antifungal activity
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2.12.3

Antiprotozoal activity

Curcumin exhibited multiple suppressive effects on the growth of many types of
parasites such as Plasmodium falciparum[72], Leishmania[73] and Giardia
lamblia[74]. Moreover, curcumin demonstrates an additive antiprotozoal activity
against Plasmodium falciparum when concurrently used with artemisinin. This
combination led to the synergistic antiprotozoal activity[75].
Silvaa et. al. have synthesized curcumin monocarbonyl derivatives and evaluated
their activity against Trichomonas vaginalis in comparison with metronidazole. Some
synthesized derivatives (3a, 3e and 5e) demonstrated a potential anti-trichomoniasis
activity comparable to metronidazole (figure 1-1 8). moreover, these derivatives are
reported to have more chemical stability and higher anti-trichomoniasis activity than
natural curcumin[76].
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Figure 1-1 8 Curcumin derivatives with a potential anti-trichomoniasis activity
2.13

Anticancer activity

Many researchers confirmed the anti-cancer activity of curcumin. Data shown that
curcumin can target transcription factors, growth factors and their receptors, which
evidence that this molecule play an important role in the regulation of cell proliferation
and apoptosis[77]. Furthermore, curcumin has been reported to suppress the mutagenic
effects of condensate results from tobacco smoking which are belonged to
benzo[α]pyrene[78], [79].
Curcumin may inhibit the proliferation and induce the apoptosis in several types of
cancer, such as:
2.13.1

Anti-breast cancer activity

Hujaily et. al have synthesized curcumin derivatives and investigated their
anticancer activity. Among synthesized analogs, two of them (figure 1-1 9) displayed
five times higher efficiency than curcumin for inducing apoptosis in the tested breast
cancer cell lines. These analogs significantly reduced the tumor size and triggered
apoptosis in vivo. Moreover, they strongly upregulated p21(WAF1) both in vitro and
in tumors. They have shown higher chemical stability and bioavailability than curcumin
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in mice [80].

Figure 1-1 9 Curcumin analogues with a potential activity against breast cancer

2.13.2

Anti-lung cancer activity

A variety of studies have showed that curcumin can modify theactivation of NFkB. Upon its activation by carcinogens, this nuclear factor can suppress apoptosis and
induce cellular transformation, proliferation, invasion, metastasis, chemoresistance,
radio-resistance, and associated inflammation[81], [82].
JZ534 (Figure 1-1 10) as a curcumin analog has been synthesized and investigated
for its anticancer effect on the lung cancer cell lines. It has exhibited an excellent antilung cancer activity by inhibiting the tumor growth, inducing the apoptosis and
upregulating the expression of apoptosis related proteins. Furthermore, JZ534 showed
a higher antitumor activity against lung cancer cell lines than curcumin[83].

Figure 1-1 10 Chemical structure of curcumin analogue JZ5
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2.13.3

Anti-cervical cancer activity

It has been shown that curcumin can act as an anti-metastatic agent and inhibits
cancer cell migration and invasion in-vitro by decreasing the expression and activity
matrix metalloproteinases MMP-2 and MMP-9[84]. Besides, curcumin has been
reported to inhibit telomerase activity in the cervical cancer and this effect could be
superior to its other anticancer effects concerning cervical cancer[85].
A novel curcumin analogue named shown below (EF24) (figure 1-1 11) was
reported to show multiple potent bioactivities and increased bioavailability compared
to curcumin[86]. He et. al. verified that this analogue is 10-20 times more effective on
cervical cancer than curcumin[87]

Figure 1-1 11 Chemical structure of curcumin analogue EF24

2.13.4

Anti-prostatic cancer activity

A recent clinical study conducted on the prostatic cancer patients has revealed that
the co-administration of curcumin with docetaxil caused a prostate-specific antigen
(PSA) response in more than a half of the patients. This response was achieved in 88%
of responders during the first 3 cycles of the treatment[88].
Chen and his colleagues have found that the new curcumin analogues (RL118
and RL121) shown in Figure 1-1 12 exhibited a potent cytotoxicity on the CRPC by
testing their effects on the PC3 and DU145 cells. These two analogs inhibited the
expression of key proteins involved in cell proliferation like nuclear factor (NF)-κB
(p65/RelA), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), p-
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4E-BP1, mammalian target of rapamycin (mTOR), p-mTOR, AKT and p-AKT[89].

Figure 1-1 12 Curcumin analogues effective against prostatic cancer

2.13.5 Anti-pancreatic cancer activity
In vitro studies of another curcumin analogs (CDF) on various pancreatic cancer
cell lines have verified its ability to inhibit the cell growth and the survival of cancer
cells (figure 1-1 13). This analog inhibited the production of VEGF and IL-6, and downregulated the expression of Nanog, Oct4, EZH2 mRNAs, as well as miR-21 and miR210 under hypoxia. CDF also led to decreased cell migration/invasion, angiogenesis,
and formation of pancreatospheres under hypoxia[90].
GO-Y030 (Figure 1-1 13) is another curcumin derivative which has a more
significant ability for inhibiting the pancreatic cancer cell lines than curcumin. This
analog shown the potent inhibition activity on cell viability and STAT3 activation[91].

Figure 1-1 13 Curcumin analogues with an anti-pancreatic cancer activity
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2.13.6

Anti-colorectal cancer activity

Since 1995, several studies have revealed the ability of curcumin in the suppression
and attenuation of the colorectal colon proliferation[92], [93],[94] .
A recent study conducted by Rajitha et al has demonstrated that the two curcumin
analogues (EF31 and UBS109) (figure 1-1 14) exhibited a significant suppression on
the colorectal cancer cell lines. Moreover, these analogues are superior to curcumin in
the term of improved aqueous solubility, potency and their pharmacokinetic profiles.
Their study shown that curcumin by inhibition of NF-κB translocation induced G0/G1
arrest and downregulated the thymidylate synthase in the colorectal cancer cells
(Rajitha et al., 2016).

Figure 1-1 14 Curcumin analogues effective against colorectal cancer
2.14

Antioxidant effect
Reactive oxygen species (ROS), formed normally during the cellular processes

•
like cellular respiration, include superoxide radical (O• ¯), hydroxyl radicals (OH
2 ),

singlet oxygen (O•) and H2O2[95]. Overproduction of ROS induces the oxidation of
cellular componentswhich lead to damage of the affected tissues. Human body can
attenuate the ROS damage by its own antioxidant defense systems which include
superoxide dismutase (SOD), catalase (CAT),

reduced glutathione (GSH), and

others[96].
Sankar et. al. reported the curcumin ability on the indirectly upregulation the
antioxidant enzymes like SOD, CAT and glutathione reductase[97]. Curcumin may also
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exhibit a synergistic antioxidant activity when concurrently combined with other
antioxidants[98].
Shang et. al. have synthesized three series of curcumin derivatives (Figure 1-1
15) and evaluated their antioxidant activity in comparison with curcumin. They found
that compounds with O- diphenoxyl- or O-dimethoxy-phenoxyl moiety may exhibit a
significantly higher antioxidant activity than those which do not have these

moieties[99].
Figure 1-1 15 A series of curcumin derivatives with an antioxidant activity

2.15

Anti-inflammatory effect
A series of studies has verified that curcumin has an anti- inflammatory effect

exerted through the suppression of NF-kB[100], [101]. Other studies have revealed that
curcumin may be responsible for the down-regulation of various inflammatory
cytokines such as tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-8,
interferon and some other chemokines[102], [103].
Paulino et. al. have synthesized a curcumin analogue (DM1) and study its antiinflammatory effect (figure 1-1 16). Results revealed that this analog has a significant
ability to suppress the iNOS (inducible nitric oxide synthase) and COX2[104].
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Figure 1-1 16 Chemical structure of the curcumin analogue DM1
2.16

Antidiabetic effect
To date, there are accumulative studies which strongly recommendedthe potential

therapeutic effect of curcumin in the management of diabetes mellitus through its
hypoglycemic, hypolipidemic, antioxidative and anti-inflammatory effects[105].
Kim et. al. reported that curcumin has the glucose-lowering effect which could be
attributed to its ability to reduce the hepatic glucose output[106]. Furthermore,
curcumin was also endorsed to attenuate the diabetic micro- and macro- vascular
complications including diabetic nephropathy[107], cardiomyopathy[108] and
retinopathy[109].
2.17

Anti-Alzheimer effect
A series of curcumin analogs had been synthesized by Chen et. al. and evaluated

for their effects on Alzheimer disease. These analogs exhibited a high inhibitory
activity of against Aβ- aggregation compared to curcumin. In this context, further
investigations have confirmed that one analog (A4) has displayed better results than the
other synthesized curcumin derivatives[110] (figure 1-1 17).

Figure 1-1 17 Chemical structure of the curcumin derivative named A4
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2.18

Cancer types used for study the effect of curcumin analogs

2.18.1

Head & neck cancer

Head and neck cancer is the sixth most common cancer, with a worldwide
incidence of 650,000 cases and 350,000 deaths annually[111].
Head and neck cancers are malignancies of the oral and nasal cavity, post-nasal
spaces (sinuses), lips, salivary glands, pharynx (hypopharynx, oropharynx and
nasopharynx), and larynx. Head and neck cancers are mostly classified as squamous
cell carcinomas (SCCs), and the remainder include adenocarcinomas, melanomas, and
sarcomas[112]. Tabaco and alcohol consumption are the most risk factors are reported
from the data related to the patients with head and neck squamous cell carcinomas
(HNSCCs)[113]
2.18.1.1

STAT

Proteins of the signal transducer and activator of transcription (STAT) is
responsible for the expression of cytokines and growth factors[114]. Because of this
important role of STAT, the expression regulation of this protein could inhibit the
cancer cell formation or improvement in many cancers including head & neck squamous
cell carcinoma (HNSCC), where hyperactivation of STAT3 is implicated in both
treatment resistance and immune escape[115]. Janus kinase (JAK) and epidermal
growth factor receptor (EGFR) are involved in the regulation of STAT3[116].
Moreover, the silencing of protein tyrosine phosphatase receptors (PTPRs) as tumor
suppressors phosphorylate and so activate the STAT3 pathway which could be involved
in the HNSCC growth[117].
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2.18.1.2

pFAK

Focal adhesion kinase (FAK) is classified as an intracellular non-receptor tyrosine
kinase, plays an important role in oncogenesis and tumor progression[118]. This protein
is involved in cell survival, proliferation, adhesion, invasion and migration[119]. The
overexpression of this protein is detected in several cancers including HNSCC[120].
The overexpression of this protein has effect also on the tumor microenvironment,
epithelial–mesenchymal transition, radiation (chemotherapy) resistance, tumor stem
cells and regulation of inflammatory factors. In vitro and in-vivo study on FAK
inhibition revealed that inhibition of this protein in cancer cells led to the reduction of
cell cycle arrest and apoptosis, significantly reduction of cell growth, invasion and
migration in HNSCC cell lines[121].
2.18.1.3

pERK1/2

Extracellular signal-regulated kinases (ERKs) or classical MAP kinases belong to
mitogen-activated protein kinases (MAPK) family of kinases, comprising p38 and c-Jun
NH2-terminal kinase[122]. These protein kinases play important roles in various
extracellular stimuli and control cell cycle progression, proliferation, cytokinesis,
transcription, differentiation, senescence, cell death, migration, GAP junction formation,
actin and microtubule networks, neurite extension and cell adhesion motility, stress
response, survival and apoptosis [123], [124]. ERK pathways could be activated with
growth factors (EGF), cytokines, and virous infection[125], [126], [127]. ERK1/2
activation is fundamental for the development and progression of cancer[128].
Overexpression of epidermal growth factor receptor (EGFR) is almost reported in
SCCHN. Experiments have shown that the inhibiting ERK signaling pathway resulted
in the downregulation of EGFR and reduced invasion[129], [130], [131], [132].
One of the important target of ERK is AP1, which can increase transcription of matrix
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metalloproteases (MMPs), such as MMP9[132], [133], [134].
2.18.1.4

pAKT

Protein kinase B (PKB) which is also known as AKT is involve in multiple cellular
responses like glucose metabolism, apoptosis cell proliferation, and cell migration. There
are another kinase called Phosphoinositide 3-kinases (PI3K) which plays important roles
in cell growth, proliferation, differentiation, motility, survival and intracellular trafficking
which are involved in cancer[135]. The activity of this protein is also important in invasion
which could be related to the AKT and mammalian target of rapamycin (mTOR). These
two proteins are effector proteins downstream the PI3K[130], [132], [136], [137].
Together, the members of the PI3K/Akt/mTOR axis interact with and contribute to the
regulation of several other signaling molecules in HNSCC[138]. The activation of AKT
was observed also in human HNSCC with the pattern of expression and localization
correlating with the progression of the lesions[139].
2.18.2

Glioblastoma

The annual incidence of primary and central nervous system tumors is 6.4 per
100,000 men and women per year. During the year 2020, 22,850 new brain and central
nervous system tumor cases were reported, making up 1.4% of all new cancer cases
(Institute 2015). There are many subtype of this brain cancer. Glioblastoma multiforme
(GBM) is classified as a is one of the glial-derived malignant primary brain tumors in
adults with a poor prognosis. It is accounting for 12–15 % of all brain tumors and
approximately 70 % of all diagnosed gliomas[140]. Although there are several treatment
options like surgery, radiotherapy and chemotherapy with temozolomide, an
imidazotetrazine derivative[141], this cancer is in the category of high mortality rate and
the average survival is only 3.3% rate at 2 years and 1.2 % at 3 years which leads to
classification of GBM as a most progressed and severe (grade IV). [142], [143], [144].

29

Since this cancer grows by infiltrating the surrounding brain tissue, it is impossible to
remove all the cancer cells from the brain by surgical resection[145], [146]. Despite the
intensive effort for improving the treatment of this disorder, there is a lack of clinical
improvement[141], [147]. The etiology of neoplasms is not known completely. The only
confirmed risk factor is high does ionizing radiation[148], [149], [150]. Moreover there
are some evidences including the report of 116 case of GBM since 1960s resulting from
radiation exposure[151]. In addition, study has shown that relatively low doses of radiation
using for the treatment of tinea capitis and skin hemangioma in children or infants could
be considered as a risk factor for GBM[152]. Moreover, data have shown the enhancement
of risk of GBM in pediatric populations and adults who are in the exposure of the
therapeutic intracranial radiation. Prasad et al. studied the effect of ionizing radiation after
the exposure of the Japanese population to atomic bomb irradiation in Nagasaki and
Hiroshima. The data have shown that all type of brain tumors including gliomas were
increased in this population[153].
Another study has shown that patients who has received treatment for lymphoid
leukemia (ALL), shown more GBM development could be because of complications
arising from the leukemia or the chemotherapeutic agents used to treat ALL[151]. There
are some more risk factors including electromagnetic field, head injury, and smoking[148],
[154], [155], [156] .
Some agricultural chemicals like organochlorides and alkylureas combined with
copper sulfates are carcinogenic are suspended because of their carcinogenic effects on
animals. Case-control studies and cohort studies on agricultural workers shown the same
results respect to the risk for brain tumors [157]. Some studies investigated the effect of
endogenous steroid hormones on the improvement of GBM, since some gliomas and
glioblastomas express estrogen receptors (ER), especially ERβ, as well as aromatase, the
enzyme responsible for the conversion of testosterone to estradiol, and possibly other
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steroid hormone receptors[158]. On the other hand, data shown that people who suffer from
allergy and infection, are more protected against GBM because of the activation of immune
surveillance mechanism[154], [159], [160].
2.18.3

Breast cancer

Breast cancer which is specified for mammalians, is classified by estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER
2)expression. This type of cancer has different clinical, pathological, and molecular
features. Statistics shown that one out of eight women experiences breast cancer in their
lifetime[161]. Some factors like lifestyle and genetic are associated with this disease[162].
Moreover, there is subtype classification based on the gene expression profiling and
immunohistochemistry including(1) Luminal A representing ER+/PR+, of low-grade and
low-Ki67 index (a proliferative marker); (2) Luminal B, ER+/PR+ of higher grade
and proliferative index; (3) HER2+ with or without ER; and (4) the “basal-like,” or triple
negative that do not express any of the three receptors[163].
There are some conventional treatment available for this cancer including ionizing
radiation (IR), chemotherapy, targeted therapy, and hormonal therapy. IR and
chemotherapy cause DNA damage. Imatinib, trastuzumab, and tamoxifen are the only
promising targeted and hormonal therapies in the market, which can inhibit the specific
function of certain type of tumor cells. In many cases, cancer cells shown resistance to the
original treatment and led to the recurrent tumors[164].
2.18.4

Pancreatic cancer

Pancreatic cancer which is the fourth leading cause of cancer related deaths led to
227 000 deaths globally per year[165]. Pancreatic cancer is a major cause of cancerassociated mortality, with a dismal overall prognosis that has remained virtually
unchanged for many decades[166]. The major problem with this cancer type is related
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to the weakly prognosis of patients with pancreatic cancer with a 5 years relative
survival rate of ~6%[167], [168]. Pancreatic cancers also have few prevalent genetic
mutations; the most commonly mutated genes are KRAS, CDKN2A (encoding
p16), TP53 and SMAD4 — none of which are currently druggable[169]. Indeed, since
most pancreatic cancers are complex at the genomic, epigenetic and metabolic levels,
there are limited therapeutical options and progress in drug development is
impeded[170]. Furthermore, the multilayered interplay between neoplastic and stromal
cells in the tumor microenvironment challenges medical treatment. Fewer than 20% of
patients have surgically resectable disease[171].
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2.19

Biological study of curcumin analogs effects

2.19.1 Cell-based assay

Cell-based assays are used to investigate the effect of test molecules on cell
proliferation or/and their cytotoxic activity which lead to the cell death. Moreover, this
type of assays is using for the measurement of receptor binding and some mechanisms
which are involved in the expression of genetic reporters, trafficking of cellular
components, or monitoring organelle function. There are variety of cell-based assays
including MTT, MST and Cell Titer Glo-2 assay which can provide the quantity of
viable cells at the end of experiment.
2.19.2 MTT assay

MTT is classified as a colorimetric assay for investigating the metabolic activity.
MTT assay is a tetrazolium reduction assay, and it is useful for high throughput
screening[172]. In this assay the mitochondria enzyme (reductase) of the viable cells
can convert MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
which has a yellow color to the formazan product which is in the purple color. Thus,
color formation can be a useful marker of viable cells. The chemical reaction of this
conversion is shown in scheme 1-1 4.

Scheme 1-1 4 chemical conversion of MTT to formazan

In this method, since the formazan product is not soluble, the solubilized reagent
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most be added prior to recording absorbance reading near to 570 nm[173].
2.19.3 MTS assay

In this assay, the dehydrogenase enzyme in the live cells convert MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) to the soluble formazan (unlike MTT assay which generate insoluble
formazan, MTS assay makes soluble formazan and so second addition of reagent to the
assay plate is not needed to solubilize formazan precipitates, thus making the MTS
assay more convenient). At the end of experiment, the absorbance will be recorded by
plate reader at 490 nm. The chemical reaction of this conversion shown in scheme 1-1
5.

Scheme 1-1 5 chemical conversion of MTS to formazan

2.19.4 Cell Titer Glo-2 assay
ATP as an energy source for living cells, is involved in many biochemical reactions.
Since ATP in dead cells degraded, there is not any ATP available in dead cells. So, ATP
is accepted as a marker for viable cells, which means that higher concentration of detected
ATP indicated higher number of living cells.
Cell Titer Glo-2 assay is working based on the measurement of cell viability based
on detected of ATP. All living cells which can make ATP are detectable by Cell Titer Glo2 assay. This has different methods like colorimetric assay, fluorescence assay and
bioluminescent assay. Bioluminescence assay is preferable by scientists because of the
higher sensitivity, simple and homogeneous protocol, and fast results.
In the bioluminescence assay, luciferase as an oxidative enzyme, use ATP of living
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cells to generate light photons. At the beginning to release of ATP for the living cells, cells
are lysed and then reagents containing firefly luciferase enzyme and substrate are added
to catalyze a two-step reaction. The first step is activation of luciferin with ATP to generate
luciferyl-adenylate and pyrophosphate as intermediates. The next step is the reaction of
intermediates with the molecular oxygen to make oxyluciferin in an electronically excited
state and CO2. Green to yellow luminescence light releases by returning the excited state
oxyluciferin to the ground state (550-570 nm). Then the intensity of luminescence signal
measured with a luminometer. The chemical reaction of this conversion shown in scheme
1-1 6.

Scheme 1-1 6 chemical conversion of Luciferin to oxyluciferin

2.19.5 Immuno-blotting assay
Immunoassay is a bioanalytical method which using antigen-antibody reactions to
detect and quantify target molecules in biological samples. This technique is widely use
in drug discovery, drug monitoring, clinical diagnostic, and food testing. Immunoassay
measures the presence or concentration of specific protein from the complex mixture of
proteins macromolecules or small molecules extracted from the cell through the use of
an antibody and antigen[174].
This technique separate proteins and macromolecules based on their weight
through gel electrophoresis. Protein on the gel then transferred to a membrane
producing a band for each protein. The membrane is then incubated with labels
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antibodies specific to the protein of interest, and unbound antibodies are washed off.
Since the specific antibody band to the specific protein, only one band should be visible
on the film. The thickness of band is related to the amount of protein presented[175].

2.20

Major barriers of curcumin's clinical efficacy
Although Curcumin exhibits several biological activities like anti-inflammatory,

antioxidant, anticancer, antiviral, and neurotrophic activity, there are some barriers for
using this compound as a drug like low oral bioavailability, low potency and low chemical
stability. Light leads to photo-degradation of this compound. Also this compound is not
stable in the acidic and basic situation and so it is not stable in the physiological condition.
(Figure 1-1 18)

Figure 1-1 18 Chemical instability of curcumin
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2.21

Aim and objectives
The overall aim of the project is design and synthesis of chemically modified

curcumin analogs to improve the potency and chemical stability for the cancer
treatment. The objectives are:
1: Chemical modification of curcumin keto enol functional groups to improve
the chemical instability, oral bioavailability, and potency of curcumin analogs.
2: Chemical modification of one of the phenolic functional group of curcumin by
click chemistry approach to improve the potency and solubility.
3: To test the newly synthesized curcumin analogs for anticancer activity in head
& neck, breast, pancreatic, and glioblastoma cancer cells.
4: Discovery of novel hit molecules targeting cytokine receptor CXCR4 by InSilico High throughput screening approach

CHAPTER THREE: DESIGN OF THE STUDY
3.1

Materials
All the chemicals, reagents and solvents utilized in the present work were

purchased from different companies. In Table 1-3 1, the undermentioned compounds
and their corresponding suppliers are listed.
Table 1-3 1 The utilized solvents, reagents and chemicals with their suppliers
Materials

Company

Glioblastoma cancer cells (GBM)

VWR

Head and neck cancer cells

VWR

Dulbecco's Modified Eagle's Medium (DMEM)

VWR

Penicillin/streptomycin

VWR

Trypsin

VWR

Phosphate buffered saline (PBS)

VWR

Trypan blue

VWR

4′,6-diamidino-2-phenylindole (DAPI)

VWR

Propidium iodide (PI)

VWR

Cell Titer Glo-2 assay dye

VWR

Absolute methanol

Sigma-Aldrich

Absolute ethanol

Sigma-Aldrich

Acetic acid glacial

Sigma-Aldrich

Acetylacetone

Sigma-Aldrich
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Dichloromethane

Sigma-Aldrich

Ethyl acetate

Sigma Aldrich

Hexane

Sigma-Aldrich

Toluene

VWR

Chloroform (D1)

VWR

Dimethyl sulfoxide (DMSO-D6)

Sigma Aldrich

Methanol anhydrous

Sigma Aldrich

Curcumin

Sigma Aldrich

Sulfuric acid

VWR

Acetic acid

VWR

2-hydrazino-4-triflouromethyl pyrimidine

VWR

6-methyl-4-trifluoromethyl prid-2yl-hydrazine

VWR

4-(6-hydrazino-4-pyrimidinyl)morpholine

VWR

3-chloro-2-hydrazino-5-(trifluoromethyl)pyridine

VWR

2-chloro-3-hydrazino pyrazine

VWR

2-hydazinyl-5-trifluoromethyl pyridine

VWR

2-hydrazino pyrazine

VWR

2-hydrazino pyrimidine

VWR

4-sulfonamido phenylhydrazine hydrochroride

VWR

Tert-butyl-4-(azidomethyl) piperidine-1-carboxylate

VWR
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Propargyl bromide

Sigma-Aldrich

3-chloro-6-hydrazino pyridazine

VWR

3,5-difluoro-2-hydrazinopyridine

VWR

2-hydrazino-3-nitropyridine

VWR

2-hydrazino4-methylquinoline

VWR

4-amino-3-hydrazino-5-mercapto-1,2,4-triazole

VWR

2-hydrazino-2-imidazoline hydrobromide

VWR

6-hydrazino[1,2,4] triazolo[4,3-b]pyridazine hydrate

VWR

3.2

Instruments

3.2.1 Instruments used in the synthesis
Equipment’s used in this project with their corresponding suppliers are
illustrated in Table 1-3 2.
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Table 1-3 2 Equipment’s utilized in this project with their companies and origins
Equipment
Balance
Hot plate and stirrer
HY-HS11
Medium pressure liquid chromatography (MPLC)

Company
Sartorius
VWR
VWR

Rotary evaporator RE 52A
Desiccator

VWR
Power sonic 410

Water bath

Kottermann Labortech

gIncubator

Sigma-Aldrich

Plate reader

Sigma-Aldrich

NMR

3.2.2

Bruker
Analytische
Messtechnik

Instruments and methods used for the identification of chemical products

3.2.2.1 Thin layer chromatography (TLC)
The purity of the synthesized compounds was performed by an ascending TLC
using precoated silica gel plates (GF254 type 60, Merck, Germany). A mixture
consisting of CH2C2: MeOH(95:5) was used as a mobile phase to elute the spots on
chromatograms. Visualization of the eluted spots was done via UV light (at 366 nm)
(Setyaningsih et al., 2014).
The results of TLC were expressed as a chromatographic measurement known
as Rf value, which is the distance traveled by the compound to that of the mobile phase
and usually expressed as a decimal fraction. Rf is the abbreviation of the Retardation
factor or Retention factor.
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3.2.2.2 Nuclear magnetic resonance (NMR) spectra
Characterization of the chemical structures of the synthesized analogues was
documented by scanning of the proton-nuclear magnetic resonance (1H-NMR)
spectra. 1H-NMR were recorded on UXNMR, Bruker Analytische Messtechnik
GmbH-600 MHz (Germany). The chemical shifts (δ) of these spectra were reported
in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard.
In 1H-NMR, the terms: singlet (s), doublet (d), triplet (t) and multiplet (m) were used
for the identification of spin-spin coupling.
The 1H-NMR was carried out in the Rice University. The CS Chem Draw Ultra
12.0 was used for drawing the chemical structures of all products and compounds
outlined in this project.
3.2.2.3 Liquid chromatography–mass spectrometry (LC-MS)
We used this technique for the detection of residual synthesized curcumin
analogs. LC-MS is doing by the combination of the separating power of liquid
chromatography with the highly sensitive and selective mass analysis capability of
triple quadrupole mass spectrometry. The spectrum were recorded by 4000 QTRAP
triple quadrupole mass spectrometer system equipped with a Turbo Ion Spray ion
source (AB Sciex. Redwood City, CA, USA). The x axes on the peak shown the mass
to charge ratio and the y axes shown the density of each peak.
3.2.3 Instruments and methods used for study the effect of curcumin analogs on
cancer cells
3.2.3.1 MTT assay
The MTT assay is a colorimetric assay for assessing cell metabolic activity. The
MTT kite was purchased from VWR and the experiment was done based on the protocol.
For doing this experiment, first, cells where cultured in the appropriate situation and then
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they were plated on the 96-well plate to quantify the amount of live and dead cells. At
the end of the experiment, cell viability was measured by plate reader at the wavelength
of 630 nm.
3.2.3.2 MTS assay
MTS and MTT both have the same basic. In the MTT assay since formazan which
generated during the experiment is insoluble, a solubilized agents should be added to the
plate. In the MTS assay, the formatted formazan is soluble and so does not need the
addition of solubilizing agents.
3.2.3.3 Cell Titer Glo-2 assay
Cell Titer Glo-2 assay, which is another type of the colorimetric assay, can measure
the cell viability based on detection of ATP. The Cell Titer Glo-2 assay kit was purchased
from VWR and the experiment was done based on the protocol. For doing this assay,
first the cancer cells were cultured in the appropriate situation and then they plated on
the 96-well plate. At the end of the experiment, luminescence measured by plate reader
at 440 nm.
3.2.3.4 Western blotting study
Western blot is used to detect the specific proteins are expressed after adding
curcumin analogs to the cancer cells. For doing this study, first proteins were extracted
from the treated and untreated cells, mixed with dodecyl sulfate, then proteins were
separated based on their size by gel electrophoresis. Proteins were transferred from the
gel onto a blotting membrane. Then this membrane went through docking which prevents
any nonspecific reaction from occurring. Then membrane was incubated with primary
antibody which can bind to the protein of interest. The unbonded primary antibody was
washed, and then the membrane was incubated with the secondary antibody which can
bind to the primary antibody. Secondary antibody also linked to the reporter enzyme
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which could make color. This step permit specific proteins to detected from a mixture
of protein.
3.2.3.5 Molecular modeling
To investigate the interactions between the curcumin analogs and the active site of
receptors, Fred module was used. Omega2 was used to generate conformations of the
ligand.
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3.3

Experimental part

3.3.1 Separation of curcuminoid
Turmeric was purchased from Sigma Aldrich containing the content 98%
curcuminoid (curcumin, desmethoxycurcumin, and bis-demethoxycurcumin) in ground
powder. Curcuminoid was purified from this mixture by using flash column
chromatography. For the purification, 5-gram of curcumin was dissolved in
dichloromethane (DCM). A column was prepared by filing it with the mixture of silica
gel as a stationary phase and eluent (mobile phase). Then the curcumin solution was
loaded on the top of the column. The less polar eluent (DCM) was used and gradually
the polarity was increased to reach to 95:5 DCM: methanol respectively. Eluent slowly
passed the column to advance the organic compounds. The fractions were collected in
twenty-two milliliter of test tubes. To check the purity of the fractions, tine layer
chromatography (TLC) with the eluent of 98:2 DCM: methanol respectively was used.
Curcumin was the most not polar compound among those three compounds so the first
spot moving on the TLC was related to the curcumin. Second spot was related to the
de-methoxycurcumin, and the last spot was related to the bis-demetoxycurcumin (figure
1-3 1). The fractions which were containing the pure compound were evaporated and
was used for the synthesis of the new curcumin analogs.

Figure 1-3 1 TLC of curcuminoid
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3.3.2

Chemical modification of curcumin keto enol functional groups to
improve the chemical instability, oral bioavailability, and potency of
curcumin analogs (specific aim 1).
Curcumin analogues have been synthesized by the equal amount of the starting

material including curcumin (1), 2-diazenylpyridine (3), in the presence of acetic acid
glacial as solvent. The mixture was continuously stirred under reflux conditions for
15 hours at 118 °C in an oil bath. After 15 hours reflux, the mixture reaction monitored
by TLC. To avoid the reaction of mixture with air, the reactions were done under the
nitrogen gas, as an inert gas. The reaction mixture was purified by column
chromatography. For doing this purification, the reaction vessel was cooled down to room
temperature. Since acetic acid boiling point is 118.5 C, the mixture of toluene and acetic
acid makes an azeotropic mixture at a concentration of about 28% acetic acid:72% toluene
and decreases the boiling point to 103C. Toluene was added to the flask, and it was
connected to the rotary and the solvent was evaporated. To decrease the time of
evaporation, rotary was connected to the vacuum pump. After solvent evaporation, the
mixture inside the vessel turned to oily and dark mixture. Then the mixture was dissolved
in DCM and methanol (9.5 and 0.5 ml, respectively). Meantime the column was prepared.
200 ml column was filled with silica gel chromatography. Then silica inside the column
was washed by 400 ml DCM. The reaction mixture was loaded on the top of column and
only DCM was as a stationary phase for column chromatography was used at the
beginning of purification and gradually the polarity was increased by adding methanol.
The purified compound was collected, the solvent was evaporated, and placed in the
dedicator to absorb the solvent, then the purified compound was weighted, and the yield
was 35%. To determinate the molecular identity and structure of the synthesized
compound, the NMR spectroscopy and LC-MS was done on the compound. Spectrums
confirm the structure of 4,4'-((1E,1'E)-(1-(pyridin-2-yl)-1H-pyrazole-3,5-diyl)bis(ethene-
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2,1-diyl))bis(2-methoxyphenol) as a curcumin analog.
To increase the yield of reaction, we keep the reaction situation the same except
adding toluene to the acetic acid as a reaction solvent. After solvent evaporation and
purification, the analog shown 30% yield.
Another attempt for increasing the yield of the analog, was increasing the amount of
hydrazine as a starting material. Twice amount of 2-diazenylpyridine was used and the
rest reaction condition remained the same. This time the analog shown 43% yield which
shown a little improvement.
Since the reaction mixture was exposed of high temperature due to the reflux
situation for a long time (15 hours), the next attempt was decreasing the reflux time to 7
hours, and the hydrazine was used twice also. At the end of the experiment, the analog
shown 62%, which was a good improvement in the yield of the analog.
Since hydrazine analogs are expensive, to make the reaction more affordable, we
used curcumin/hydrazine ration of 1:1.2 and the experiment was done for 7 hours under
reflux condition, which led to the yield of 61%.
We also used MPLC (medium pressure liquid chromatography) for the purification
of this curcumin analog to check the efficacy of this purification method on the yield of
the curcumin analogs. MPLC is basically a liquid column chromatography with sufficient
pressure generated by a pump to push solvent through a column containing fine mesh
packing materials. The summary of the attempted reactions are shown in table 1-3 3.
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Table 1-3 3 summery of attempted reactions
Number of
attempts Curcum Hydrazine
in
1

1eq

1eq

Solvent

Reaction condition

Yield%

Acetic Acid

Reflux, 15 hours

35%

2

1eq

3

1eq

2eq

4

1eq

2eq

Acetic acid

Reflux, 7 hours

62%

1eq

1.2eq

Acetic acid

Reflux, 7 hours

61%

1eq

Acetic acid + Toluen

Acetic acid

Reflux, 15 hours

Reflux, 15 hours

30%

43%

5
The suggested mechanism for the synthesis of this analogues is shown in scheme 1-3 1.
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Scheme 1-3 1 suggested mechanism of pyrazole curcumin analogs
Since ketones are more active than enols, hydrazine nitrogen make a reaction with the
ketone group and by releasing one molecule of water, make an imine group. Then enol
group, which is more activated in the presence acetic acid, make a reaction with the second
nitrogen of hydrazine and led to the release of another molecule of water. So, the result of
all these steps is making the new curcumin analogs by converting keto-enol group to
pyrazole group.
Here are other synthesis methods were also tested which ended to no results.
✓ Checking different reaction condition:
•

Curcumin (1) was stirred in methanol and then hydrazine (3) was added to
the flask followed by adding HCl (6N). The mixture was stirred overnight
at room temperature.

•

Curcumin (1) was stirred in methanol and then hydrazine (3) was added to
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the flask followed by adding NaHCO3. The mixture was in reflux for 15
hours.
•

Curcumin (1) and hydrazine (3) were in reflux in acetonitrile for 15 hours.

•

Curcumin (1) and hydrazine (3) were in reflux in acetonitrile and acetic
acid (stoichiometric amount) for 15 hours

✓ Checking different extraction condition:
Since acetic acid is soluble in water, we tried to extract the acetic acid by liquid-liquid
extraction which is also known as solvent extraction. This technique is using to separate
compounds, based on their relative solubilities in two different immiscible liquids, usually
water and an organic solvent. Since curcumin analogs were soluble in acetic acid, we used
acetic acid as an organic solvent, and since acetic acid is soluble in water, it was used as
an inorganic solvent. Different method of solvent extraction in the presence of acetic acid
and water were tested which are including:
•

Extraction with ethyl acetate and water

•

Extraction with ethyl acetate and brine

•

Extraction with ethyl acetate and sodium bicarbonate solution

The compound supposed to go to the organic solvent, and acetic acid go to the
inorganic solvent. So, after the extraction, for absorbing possible water molecule in the
extracted organic solvent, calcium chloride (CaCl2) or magnesium sulfate (MgSO4) as
molecular sieve the was added to this flask (molecular sieves are materials with pores of
uniform size and are using for absorbing the moisture). After 10 minutes, the solution was
filtered to remove the molecular sieve, then ethyl acetate was evaporated with rotary.
Since TLC from the organic and inorganic solvent revealed that curcumin analog is

50

soluble in both solvents, this extraction method did not work.

✓ Checking different reaction solvents
Choosing of an appropriate solvent may be also regarded as an important task to
provide a suitable solubility for the reactants, intermediates, and products. Various
solvents such as EtOAc, DMF, 1,4- dioxane, acetonitrile and toluene are appeared to be
reasonable options. Moreover, EtOAc was found to be an excellent solvent for the
synthesis of curcumin and its analogues with an improvement in the yield. This can be
attributed to the high solubility of the reactants, intermediates, and products[176]. Since
during the reaction, water molecule which is soluble in acetic acid was released, it makes
acetic acid as an appropriate solvent for these reactions.
After optimizing the reaction condition, several curcumin analogs were synthesized.
The general scheme of reaction shown in scheme 1-3 2 and the structure of reagents and
products are shown in table 1-3 4.
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Scheme 1-3 2 general scheme of synthesis of pyrazole curcumin analogs

Table 1-3 4 chemical structure of pyrazole curcumin analogs
Compound
number

R1

R2

Compound structure

Yield%

OCH3
65

49

OCH3
63

50

OCH3
65

51

57
OCH3

73

52

58

OCH3

52

65
59

OCH3

60

OCH3

65

H

70

OCH3

65

OCH3

70

85

68

81

53

OCH3
86
70

✓ Synthesis of 4,4'-((1E,1'E)-(1-(6-chloropyridazin-3-yl)-1H-pyrazole-3,5diyl)bis(ethene-2,1-diyl))bis(2-methoxyphenol) (49)
Compound 49 was synthesized from purified curcumin and 3-chloro-6-hydrazino
pyrazine. Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom flask followed by
adding 3-chloro-6-hydrazino pyrazine (3 mmol, 1.4 g). 10 ml acetic acid was added to the
flask. A magnet was placed inside the flask and the flask was located inside the silicon oil
as a heating bath and place it on the hat plate stirrer. To do the reaction under the reflux
condition, flask was connected to the water-cooled condenser which is typically open to
the atmosphere at the top. To avoid the air reaction with the compounds inside the flask,
nitrogen balloon was placed on the top pf the water-cooled condenser. Flask was heated
in order to boil the reaction mixture, vapors produced from the mixture are condensed by
the condenser and return to the vessel through gravity. The temperature was fix on 118 C
which is the boiling point of acetic acid.
The reaction was monitored every half an hour by the TLC. For doing the TLC,
four spots including curcumin and hydrazine as starting materials, the reaction mixture
and the mixture of these three spots were checked, to check if still we have the starting
materials inside the flask. After 8 hours the reaction was completed and cooled down to
the room temperature. 5 ml of toluene was added to the flask and the flask was connected
to the rotary for the solvent evaporation. The color of the mixture inside the flask was
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black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Only DCM was
used at the beginning of purification and gradually the polarity was increased by adding
methanol. The purified compound was collected, the solvent was evaporated, and placed
in the dedicator to absorb the solvent. Hydrogen Nuclear Magnetic Resonance (H-NMR)
was done to confirm the molecular structure of the curcumin analog. Dimethyl sulfoxide
(6d) (DMSO) was used as a solvent of H-NMR
The peak on 2.5 ppm was related to the DMSO, and two single peaks which are
located on 3.4 ppm are related to two methoxy groups. Pick on 5.6 ppm which is doublet
is related to two hydrogens in the pyridazine. Peaks from 4.8 to 5.7 ppm are related to the
aromatic group. Two peaks on 6.3 and 8.4 ppm are related to two hydroxyl group. The HNMR confirm the structure of the curcumin analog. The yield of the reaction was 65%.

✓ Synthesis of 4,4'-((1E,1'E)-(1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole3,5-diyl)bis(ethene-2,1-diyl))bis(2-methoxyphenol) (50)
Compound 50 was synthesized from purified curcumin and 6-methyl-4trifluoromethyl prid-2yl-hydrazine. Curcumin (3mmol, 1.1 g) added to the 25 ml round
bottom flask followed by adding 6-methyl-4-trifluoromethyl prid-2yl-hydrazine (3 mmol,
1.6 g). 10 ml acetic acid was added to the flask, and the next steps was repeating the steps
done for the synthesis of compound 49.
The reaction was monitored every half an hour by the TLC. After 6 hours the
reaction was completed and cooled down to the room temperature. 5 ml of toluene was
added to the flask and solvent was evaporated the same way we did for the purification of
compound 49. H-NMR was done to confirm the molecular structure of the curcumin
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analog. Dimethyl sulfoxide (6d) (DMSO) was using as a solvent of H-NMR.
The peak on 2.5 ppm was related to the DMSO, single peak at 3.5 ppm is related
to the methyl group on pyridine group, and two single peaks which are located on 3.85
ppm are related to two methoxy groups. Pick on 5.6 ppm which is doublet is related to two
hydrogens in the pyridazine. The peaks from 6.8 to 8.2 ppm are related to the aromatic
groups. Two peaks on 9.5 and 9.6 ppm are related to two hydroxyl group. The H-NMR
confirm the structure of the curcumin analog. The yield of the reaction was 63%.

✓ Synthesis of 4,4'-((1E,1'E)-(1-(4-(trifluoromethyl)pyrimidin-2-yl)-1H-pyrazol-3,5diyl)bis(ethene-2,1-diyl))bis(2-methoxyphenol) (51)
Compound 51 was synthesized from purified curcumin and 2-hydrazino-4triflouromethyl pyrimidine. Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom
flask followed by adding and 2-hydrazino-4-triflouromethyl pyrimidine (3 mmol, 1.53 g).
10 ml acetic acid was added to the flask. The next steps of synthesizing was the same as
we did for the synthesis of compound 49.
The reaction was monitored every half an hour by the TLC. After 8 hours the
reaction was completed and cooled down to the room temperature. 5 ml of toluene was
added to the flask and solvent was evaporated by using rotary. The color of the mixture
inside the flask was black after evaporation. Compound 51 was purified in the same way
the compound 49 was purified. H-NMR was done to confirm the molecular structure of
the curcumin analog. Dimethyl sulfoxide (6d) (DMSO) was using as a solvent of H-NMR.
The peak on 2.5 ppm was related to the DMSO, single peak at 3.5 ppm is related
to the methyl group on pyridine group, and two single peaks which are located on 3.85
ppm are related to two methoxy groups. Pick on 5.6 ppm which is doublet is related to two
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hydrogens in the pyridazine. The peaks from 6.8 to 8.2 ppm are related to the aromatic
groups. Two peaks on 9.5 and 9.6 ppm are related to two hydroxyl group. The H-NMR
confirm the structure of the curcumin analog. The yield of the reaction was 65%.

✓ Synthesis of 4,4'-((1E,1'E)-(1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole-3,5diyl)bis(ethene-2,1-diyl))bis(2-methoxyphenol) (57)
Compound 57 was synthesized from purified curcumin and 2-hydazinyl-5trifluoromethyl pyridine. Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom flask
followed by adding and 2-hydrazino-4-triflouromethyl pyrimidine (3 mmol, 0.433 g). 10
ml acetic acid was added to the flask, and the next steps was repeated like compound 20.
The reaction was monitored every half an hour by the TLC. After 7 hours the
reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 20. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 57 was
purified in the same way that compound 20 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 73%.

✓ Synthesis of 4,4'-((1E,1'E)-(1-(pyrazin-2-yl)-1H-pyrazole-3,5-diyl)bis(ethene-2,1diyl))bis(2-methoxyphenol) (58)
Compound 58 was synthesized from purified curcumin and 2-hydrazino pyrazine.
Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom flask followed by adding and
2-hydrazino-4-triflouromethyl pyrimidine (3 mmol, 0.33 g). 10 ml acetic acid was added
to the flask, and the next steps was repeated like compound 49.
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The reaction was monitored every half an hour by the TLC. After 7 hours the
reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 20. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 58 was
purified in the same way that compound 49 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 52%.

✓ Synthesis of 4,4'-((1E,1'E)-(1-(pyrimidin-2-yl)-1H-pyrazole-3,5-diyl) bis (ethene-2,1diyl))bis(2-methoxyphenol) (59)
Compound 59 was synthesized from purified curcumin and 2-hydrazino
pyrimidine. Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom flask followed by
adding and 2-hydrazino-4-triflouromethyl pyrimidine (3 mmol, 0.33 g). 10 ml acetic acid
was added to the flask, and the next steps was repeated like compound 49.
The reaction was monitored every half an hour by the TLC. After 7 hours the
reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 49. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 59 was
purified in the same way that compound 49 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 65%.

✓ Synthesis of 4-(3,5-bis((E)-4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)
benzenesulfonamide (60)
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Compound 60 was synthesized from purified curcumin and 4-sulfonamido
phenylhydrazine hydrochroride. Curcumin (3mmol, 1.1 g) added to the 25 ml round
bottom flask followed by adding and 2-hydrazino-4-triflouromethyl pyrimidine (3 mmol,
0.669 g). 10 ml acetic acid was added to the flask, and the next steps was repeated like
compound 20. The reaction was monitored every half an hour by the TLC. After 8 hours
the reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 49. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 60 was
purified in the same way that compound 49 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 85%.

✓ Synthesis of 4-((E)-2-(3-((E)-4-hydroxystyryl)-1-(3-methyl-5-(trifluoromethyl)pyridin2-yl)-1H-pyrazol-5-yl)vinyl)-2-methoxyphenol (65)
Compound 65 was the second spot of reaction of curcumin and 6-methyl-4trifluoromethyl prid-2yl-hydrazine. This compound was purified from the same
chromatography column of compound 50. This spot was separated after the separation of
compound 50. The yield of the reaction was 70%.

✓ Synthesis of 4,4'-((1E,1'E)-(1-(3-nitropyridin-2-yl)-1H-pyrazole-3,5-diyl) bis(ethene2,1-diyl))bis(2-methoxyphenol) (68)
Compound 68 was synthesized from purified curcumin and 2-hydrazino-3nitropyridine. Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom flask followed
by adding and 2-hydrazino-4-triflouromethyl pyrimidine (3 mmol, 0.462 g). 10 ml acetic
acid was added to the flask, and the next steps was repeated like compound 49.
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The reaction was monitored every half an hour by the TLC. After 7 hours the
reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 20. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 68 was
purified in the same way that compound 49 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 65%.

✓ Synthesis 4-((E)-2-(5-((E)-4-hydroxy-3-methoxystyryl)-1-(pyridin-2-yl)-1H-pyrazol-3yl)vinyl)-2-methylphenol (81)
Compound 81 was synthesized from purified curcumin and 2-hydrazinylpyridine.
Curcumin (3mmol, 1.1 g) added to the 25 ml round bottom flask followed by adding and
2-hydrazinylpyridine (3 mmol, 0.31 g). 10 ml acetic acid was added to the flask, and the
next steps was repeated like compound 49.
The reaction was monitored every half an hour by the TLC. After 8 hours the
reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 49. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 81 was
purified in the same way that compound 49 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 70%.

✓ Synthesis of 4-((E)-2-(1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-3-((E)-4-hydroxy-3methylstyryl)-1H-pyrazol-5-yl)vinyl)-2-methoxyphenol (86)
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Compound 86 was synthesized from purified curcumin and (2,6-dichloro-4(trifluoromethyl)phenyl)hydrazine. Curcumin (3mmol, 1.1 g) added to the 25 ml round
bottom flask followed by adding and 2-hydrazino-4-triflouromethyl pyrimidine (3 mmol,
0.73 g). 10 ml acetic acid was added to the flask, and the next steps was repeated like
compound 49. The reaction was monitored every half an hour by the TLC. After 8 hours
the reaction was completed and cooled down to the room temperature. The solvent was
evaporated the same way we did for compound 49. The color of the mixture inside the
flask was black after evaporation. The mixture was dissolved in DCM: methanol (9.5:0.5
respectively) and then loaded on the prepared chromatography column. Compound 86 was
purified in the same way that compound 49 was purified. H-NMR was done to confirm
the molecular structure of the curcumin analog. The yield of the reaction was 70%.

3.3.3

Chemical modification of one of the phenolic functional group of
curcumin by click chemistry approach to improve the potency and
solubility (specific aim 2)

Some curcumin analogs were made also by click chemistry on one of the hydroxyl
groups to do the azide-alkyne cycloaddition. This reaction was done in the presence of
propargyl bromide, potassium carbonate as a catalyst, in the presence of
dimethylformamide at room temperature for 48 hours. Since curcumin is a symmetric
molecule, propargyl could be added to one or both side of the curcumin and lead to the
generation of two products: mono-propargyl (6) and dipropargyl curcumin (7). Since most
of the research study shown the most biological activity of mono-propargyl curcumin, we
tried to increase the yield of this product[177], [178].
The first experiment was done on this reaction was using curcumin/propargyl bromide
1:2. After 48 hours reaction, the yield of mono propargyl curcumin was 5%. To increase
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the yield of this analog, we decrease the amount of propargyl bromide to 1.2 equivalent.
After 48 hours the yield of this analog increased to 53%. We decreased again the amount
of propargyl bromide to 0.8 equivalent and the yield was increased to 85%. The reaction
mixture was purified by chromatography column with the eluent of chloroform: methanol
(9:1 respectively), and since it was not completely pure, another chromatography column
was used with ethyl acetate: hexane (5:5) as eluent. The pure product was used for the
next step which is azide-alkyne cycloaddition by click chemistry. The H-NMR confirm
the structure of this curcumin analog. The general scheme of reaction shown in scheme
1-3 3. The summary of the attempted reactions are shown in table 1-3 5.

Table 1-3 5 summery of attempted reactions
Num Curcumin Propargy Solvent
l
ber
bromide
of
atte
mp
ts
1

1eq

2

1eq

3

1eq

2eq

Reaction condition

DMF

1eq Acetic acid + Toluen

2eq

Acetic acid

RT, 48 hours

Reflux, 15 hours

Reflux, 15 hours

Yield
Mono%

Yield Di%

5%

95%

53%

35%

85%

5%
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Scheme 1-3 3 general scheme of synthesis of pyrazole curcumin analogs

The suggested mechanism is shown in scheme 1-3 4.

Scheme 1-3 4 suggested mechanism of synthesis of propargyl curcumin analog
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The next step was azide-alkyne cycloaddition which is known as click reaction. Click
chemistry is a reaction with the high yield and byproducts can be removed without
chromatography. It is stereospecific, simple to perform, and can be conducted in easily
removable or benign solvents. This kind of rection is interesting reactions for
pharmaceutical, materials and other industries in capabilities for generating large libraries
of compounds for screening in discovery research. Several types of reaction have been
identified that fulfill these criteria, thermodynamically-favored reactions that lead
specifically to one product, such as nucleophilic ring opening reactions of epoxides and
aziridines, non-aldol type carbonyl reactions, such as formation of hydrazones and
heterocycles, additions to carbon-carbon multiple bonds, such as oxidative formation of
epoxides and Michael Additions, and cycloaddition reactions.
In our project, to do the click chemistry reaction, the equal amount of propargyl
curcumin (6) and azide derivative in the presence of copper (II) sulfate (as a catalyst) and
sodium ascorbate refluxed in tetrahydro furan, ethanol and water as solvent for 3 hours.
To remove cooper (II) sulfate from the reaction, the reaction mixture was washed with
DCM, and the purity of the product was checked by TLC. The column chromatography
was done to purify this curcumin analog (the stationary phase was DCM and the polarity
was increased gradually). The dried product shown 62 percent yield. The structure of the
analog was confirmed by H-NMR and LC-MS.
To increase the yield of azide curcumin derivative, we increased the amount of azide
to 1.2 equivalent. The yield was calculated after the purification and it was 76%.
The general scheme of reaction shown in scheme 1-3 5.
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Scheme 1-3 5 general scheme of synthesis of triazole curcumin analogs

The suggested mechanism for this reaction shown in scheme 1-3 6.

Scheme 1-3 6 suggested mechanism of synthesis of triazole curcumin analogs

The summery of attempt shown in table 1-3 6.
The general scheme of reaction shown in scheme 1-3 7 and the structure of reagents
and products are shown in table 1-3 7.
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Table 1-3 6 summery of attempted reactions
Num Curcumin Azide
ber of propargyl
atte
mp
ts
1

2

1eq

1eq

1eq

1eq

Solvent

Reaction condition

Yield%

THF, EtOH, Water

Reflux, 6h
Sodium Ascorbate,
CuSO4

62%

THF, EtOH, Water

Reflux, 6h
Sodium Ascorbate,
CuSO4

76%
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Scheme 1-3 7 general reaction of synthesis of triazole curcumin analogs

Table 1-3 7 chemical structure of triazole curcumin analogs
Compound
number

R

Compound structure

Yield

75
77

75
78

73
79

80

75

67

✓ Synthesis of (3R,4S,5R)-2-(4-((4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3methoxyphenyl)-3-oxohepta-1,4,6-trien-1-yl)-2-methoxyphenoxy)methyl)-1H-1,2,3triazol-1-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (77)
Compound 77 was synthesized from purified propargyl curcumin (6) and
(3R,4S,5R)-2-(triaz-2-en-1-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate under reflux
condition for eight hours under inert nitrogen gas. After eight hours, the reaction was
monitored by TLC, and then the solvent was evaporated with rotary. The reaction mixture
was washed by thirty milliliters of DCM to remove the copper (II) sulfate. To get more
purified product, we used the column chromatography. The stationary phase was DCM
and the polarity was increased gradually by adding MeOH. The H-NMR confirmed the
structure of compound 77. The yield of the reaction was 75%. Peaks at 1.7 and 2 ppm are
related to the methyl group on xylose.

✓ Synthesis of tert-butyl 2-(4-((4-((4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3methoxyphenyl)-3-oxohepta-1,4,6-trien-1-yl)-2-methoxyphenoxy)methyl)-1H-1,2,3triazol-1-yl)methyl)piperidin-1-yl)acetate (78)
Compound 78 was synthesized from purified propargyl curcumin (6) and tert-butyl
2-(4-(triaz-2-en-1-ylmethyl)piperidin-1-yl)acetate under reflux condition for eight hours
under inert nitrogen gas. After eight hours, the reaction was monitored by TLC, and then
the solvent was evaporated with rotary. The next steps of purification were the same as
the purification of compound 77. The yield of the reaction was 75%.

✓ Synthesis of (4-((4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-3oxohepta-1,4,6-trien-1-yl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (79)
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Compound 79 was synthesized from purified propargyl curcumin (6) and tert-butyl
2-(4-(triaz-2-en-1-ylmethyl)piperidin-1-yl)acetate under reflux condition for eight hours
under inert nitrogen gas. After eight hours, the reaction was monitored by TLC, and then
the solvent was evaporated with rotary. The next steps of purification were the same as
the purification of compound 77. The yield of the reaction was 73%.

✓ Synthesis of methyl 2-(4-((4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)3-oxohepta-1,4,6-trien-1-yl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate
(80)
Compound 80 was synthesized from purified propargyl curcumin (6) and tert-butyl
2-(4-(triaz-2-en-1-ylmethyl)piperidin-1-yl)acetate under reflux condition for eight hours
under inert nitrogen gas. After eight hours, the reaction was monitored by TLC, and then
the solvent was evaporated with rotary. The next steps of purification were the same as
the purification of compound 77. The yield of the reaction was 75%.
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3.3.4

Test the newly synthesized curcumin analogs for anticancer activity in
head & neck, breast, pancreatic, and glioblastoma cancer cells
(specific aim 3)

3.3.4.1

Head & neck cancer

3.3.4.1.1 MTT assay
MTT assay is The sensitivity of cells to pyrazole compounds was measured using the
MTT-based colorimetric cell proliferation kit (Roche Applied Science, Mannheim,
Germany). Briefly, 5000 cells/well were plated in a 96 well plate. The next day, cells were
treated with different concentrations of pyrazole compounds. After 72 hours, 10 µl/well
of MTT solution was added to each well and further incubated for 4 hours at 37oC. The
formazan crystals formed in the wells were solubilized by adding solubilization solution
and incubating the plates at 37oC overnight. The plates were read at 590 nm on a
Spectramax 190 plate reader. The percentage cell growth inhibition for each treatment
group was calculated by adjusting the untreated control group to 100%. In the thesis we
examined two different head & neck cancer cell lines including CAL 24 and UM-SCC74A. the results are shown below. The results of anticancer activity of curcumin analogs
on UM-SCC-74A and CAL 24 is shown in table 1-3 8 and figure 1-3 2, and table 1-3 9
and figure 1-3 3, respectively.
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Table 1-3 8 MTT results of anti-cancer activity of curcumin analogs on UM-SCC-74A
Dose

0

0.625

1.25

2.5

5

10

20

40

Mean Com
#81

100.0

108.9

110.6

108.1

107.1

94.1

50.3

-2.6

Com
#82

100.0

109.9

119.3

116.7

125.3

113.1 38.3

1.2

Com
#83

100.0

86.6

91.2

93.1

91.3

61.4

3.5

2.6

Com
#84

100.0

100.6

110.3

119.5

81.5

20.3

4.9

4.6

Com
#85

100.0

101.8

110.5

109.6

111.2

114.3 97.3

59.4

Com
#77

100.0

101.2

91.8

95.1

64.7

29.0

17.6

8.4

Com
#49

100.0

104.1

108.8

109.5

64.8

11.6

0.3

0.7

Com
#50

100.0

123.5

117.2

114.3

110.3

85.1

13.0

0.5

Com
#81

0.0

4.4

3.0

7.8

8.4

6.2

4.5

0.7

Com
#82

0.0

6.4

5.9

5.3

4.4

5.4

2.1

1.1

Com
#83

0.0

9.2

9.1

8.7

7.3

7.3

2.2

1.8

Com
#84

0.0

8.1

6.7

7.5

5.2

2.5

1.9

1.0

Com
#85

0.0

6.7

7.6

5.8

7.1

5.4

4.5

3.5

Com
#77

0.0

7.8

2.2

5.3

3.7

1.7

0.5

1.2

Com
#49

0.0

6.9

5.8

5.5

4.9

2.5

0.2

0.1

Com
#50

0.0

5.9

6.2

6.0

6.3

4.5

2.9

0.1

SD
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Figure 1-3 2 The graph of MTT results of anticancer activity of curcumin analogs on
UM-SCC-74A
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Table 1-3 9 MTT results of anticancer activity of curcumin analogs on CAL 24
Dose

0

0.625

1.25

2.5

5

10

20

40

Mean Com
#81

100.0

108.9

110.6

108.1

107.1

94.1

50.3

-2.6

Com
#82

100.0

109.9

119.3

116.7

125.3

113.1 38.3

1.2

Com
#83

100.0

86.6

91.2

93.1

91.3

61.4

3.5

2.6

Com
#84

100.0

100.6

110.3

119.5

81.5

20.3

4.9

4.6

Com
#85

100.0

101.8

110.5

109.6

111.2

114.3 97.3

59.4

Com
#77

100.0

101.2

91.8

95.1

64.7

29.0

17.6

8.4

Com
#49

100.0

104.1

108.8

109.5

64.8

11.6

0.3

0.7

Com
#50

100.0

123.5

117.2

114.3

110.3

85.1

13.0

0.5

Com
#81

0.0

4.4

3.0

7.8

8.4

6.2

4.5

0.7

Com
#82

0.0

6.4

5.9

5.3

4.4

5.4

2.1

1.1

Com
#83

0.0

9.2

9.1

8.7

7.3

7.3

2.2

1.8

Com
#84

0.0

8.1

6.7

7.5

5.2

2.5

1.9

1.0

Com
#85

0.0

6.7

7.6

5.8

7.1

5.4

4.5

3.5

Com
#77

0.0

7.8

2.2

5.3

3.7

1.7

0.5

1.2

Com
#49

0.0

6.9

5.8

5.5

4.9

2.5

0.2

0.1

Com
#50

0.0

5.9

6.2

6.0

6.3

4.5

2.9

0.1

SD
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Figure 1-3 3 the graph of MTT results of anticancer activity of curcumin analogs on CAL24

3.3.4.1.2 Western blot analysis
To investigate the mechanism of action of the curcumin analogs, western blot was
done. Since there are some proteins including pSTAT3, pFAK, pERK1/2, pAKT, and
GAPDH are involved in the improvement of head & neck cancer, the inhibition effect of
these analogs was checked by western blotting were checked. Figure 1-3 4 shown the
western blotting analysis of curcumin analogs on UM-SCC-74 A and CAL-24.
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Figure 1-3 4 the western blotting analysis of curcumin analogs on UM-SCC-74 A

3.3.4.1.3 Molecular docking
To determine the binding mode, molecular docking of one of the pSTAT3 active
compounds, into the SH2 domain of STAT3 was carried out using Fred module. Omega2
was used to generate conformations of the ligand.
The crystal structure of STAT3β (pdb code 1BG1) was used to generate the receptor
grid with the help of mak- ereceptor. A hydrogen bond constraint was applied for Arg609,
one of the crucial amino acid in the phospho-tyrosine binding pocket. The predicted
binding mode of pyrazolecompound showed hydrogen bond formation between the
methoxy substituent and Arg609. There is a cation-pi interaction between Lys 591 and the
phenyl ring of pyrazole compound. (figure 1-3 5)
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Figure 1-3 5 docking study of SH-2 domain of STAT3 and compound 81
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3.3.4.2

Human breast cancer cells and pancreatic adenocarcinoma cancer

3.3.4.2.1 MTS assay
The anti-cancer activity of curcumin and its analogues was assessed by the CellTiter
96® AQueous One Solution Cell Proliferation Kit (Promega Corporation, Madison, WI)
(MTS assay) method. Briefly, cancer cells (5×103) were plated in 96 well-plate and
allowed overnight to attach. These cells were treated with 20 µM curcumin analogues for
48 hrs. Then, 20 µL of MTS reagent was added to each well and incubated for 2 hours in
incubator. Then the optical absorbance was measured at 492 nm using a 96-well
microplate reader.
Figure 1-3 6 and figure 1-3 7 shown the effect of curcumin analogs on MDA-MB
231 as a human breast cancer and HPAF as a human pancreatic cancer, respectively.

Figure 1-3 6 the effect of curcumin analogs on MDA-MB 231
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Figure 1-3 7 the effect of curcumin analogs on HPAF

3.3.4.3

Glioblastoma cancer

3.3.4.3.1 CellTiter-Glo Assay
The anti-cancer activity of curcumin analogs were tested on MG118 cells as grade
IV glioblastoma multiforme by Cell Titer Glo-2 assay. In this experiment, Human GBM
cells treated with curcumin analogs for 24 hr. After 24 hours of exposure incubated the
cells were treated with CellTiter-Glo assay reagent (Promega). Luminescence was
measured as per the manufacturer’s instruction using a plate. The CellTiter-Glo®
Luminescent Cell Viability Assay to determine the number of viable cells in culture based
on quantitation of the ATP present, which signals the presence of metabolically active
cells. A luminescent signal is proportional to the amount of ATP present. The amount of
ATP is directly proportional to the number of cells present in the culture.

CHAPTER FOUR: RESULTS & DISCUSSSION
4.1

Antitumor activity
In spite of having more than two centuries of scientific history, curcumin is still

attracting researchers worldwide and there is an accumulative research papers which
reported the beneficial effects of curcumin in the treatment of several types of cancer. In
this field, curcumin may act as chemotherapeutic, chemo-preventive or adjuvant agent and
mediates its action by modulating the activity of many molecular targets[179]. In spite of
the advantages of curcumin, the application of curcumin in cancer management is limited
by its poor stability and low oral bioavailability. Curcumin molecule can penetrate the cell
membrane and interact with the fatty acyl chains via hydrogen binding and hydrophobic
interactions, resulting in shallow intracellular availability of curcumin[180].
In the present work, the antitumor activities of curcumin and its synthesized
analogues were studied against CAL 27 and UM-SCC-74A as head and neck cancer cells,
MDA-MB 231 as a human breast cancer, HPAF as pancreatic adenocarcinoma cells, and
MG118 as glioblastoma multiforme cells by performing MTT, MST, and cell titer glo-2
assay, as well as immunoblotting.
The MTT assay is frequently used as an indicator of the cell viability and
proliferation. The MTT assay is working based on the fact that the number of viable cells
is constantly correlated with their mitochondrial activities which can be reflected via the
conversion of the yellow tetrazolium salt of MTT into purple formazan. The resultantcolored solution is quantified by measuring the absorbance using a multi-well
spectrophotometer. The darker colored solution indicated the high number of the viable
and metabolically active cells[181].
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4.1.1

Analysis the anticancer activity of curcumin analogs on CAL 27 and UMSCC-74A head & neck cancer cell lines
The cytotoxicity of all synthesized pyrazole and triazole curcumin analogs were

tested against two head and neck cancer cell lines by MTT assay. The tested analog
concentrations were 0.625, 1.25, 2.5, 5, 10, 20, 40 µM. MTT assay as a colorimetric assay
was using to identify the quantity of dead and live cells in the 96 well-plates. During this
assay, tetrazolium dye is converted to the insoluble formazan which has a purple color by
NAD(P)H-dependent cellular oxidoreductase enzymes. Dimethyl sulfoxide as a
solubilized agent was added to the well-plate to dissolve formazan.
On UM-SCC-74A, from pyrazole analogs, compound 49 with the IC50 of 6 µM
shown the best anticancer activity against this cancer cell line after 72 hours. Compounds
83 ,50, 81, 84, 82 with the IC50 of 12 µM, 20.1 µM, 21.4 µM, 21.7 µM, and 82 23.8 µM
respectively shown good anticancer activity against these two cancer cell lines. Two
triazole curcumin analogs were tested against these two cancer cell lines. Results shown
that while compound 77 showed good anticancer activity (IC50: 10.5 µM), compound 85
did not show any anticancer activity.
The same analogs were tested on CAL27 by the same concentration and same
method. Results have shown that from pyrazole analogs, compounds 49, 77, 83 and 84
with the IC50 of 5.1 µM, 6.3 µM and 6.3 µM respectively, and from triazide curcumin
analogs, compound 77 with the IC50 5.4 µM shown the best activity against CAL27, after
72 hours. Compound 85 shown the lowest anticancer effect in both cancer cell lines.
To figure out the mechanism of action of these drugs, the immunoblotting was done
to understand the effect of these analogs on the specific protein expression like STAT3,
FAK, ERK1/2, AKT and GAPDH. The results shown that these analogs downregulated
the expression of STAT3. Docking study was done to investigate the interaction between
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curcumin analogs and receptor binding site. Omega2 was used to generate conformations
of the ligand. The binding model of compound 81 with the active site of STAT3-SH2
shown that there is a hydrogen bond with arginine with the methoxy and hydroxy groups
on the one side of the analogs. In addition, this drug can make a π-π interaction with lysine
and proline with the benzyl groups on its both sides.
This data emphasized the importance of hydrogen bond between the side chain of
curcumin analogs and receptor which will be decreased by modification on the curcumin
side chain. Moreover, some triazide curcumin analogs has a big molecular weight which
cannot follow the Lipinski’s rule.

4.1.2

Analysis the anticancer activity of curcumin analogs on DA-MB-231 as
human breast cancer cell line
The cytotoxicity of all synthesized pyrazole and triazole curcumin analogs were

tested against DA-MB-231 cell lines by MTS assay. The tested analog concentrations
were 0.625, 1.25, 2.5, 5, 10, 20, 40 µM. MTS which is using to assess cell proliferation,
cell viability and cytotoxicity, works based on reduction of the MTS tetrazolium
compound by viable mammalian cells to generate a colored formazan dye which is soluble
in cell culture media. NAD(P)H-dependent dehydrogenase enzymes in metabolically
active cells are responsible for this conversion, and then the formazan dye was quantified
by measuring the absorbance at 490-500 nm.
The data related to DA-MB-231 shown that among curcumin analogs, compounds
6 and 81 shown the best anticancer activity against this cancer cell line after 72 hours. On
the other hand, triazole curcumin analogs showed weak anticancer activity against DAMB-231. Like human head & neck cancer cell line, these data also might be due to the
hydrogen bond interactions between the side chain of curcumin analogs and receptors, as
well as a big molecular weight of some triazide curcumin analogs.
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4.1.3

Analysis the anticancer activity of curcumin analogs on HPAF as pancreatic
cancer cell line
The cytotoxicity of all synthesized pyrazole and triazole curcumin analogs were

tested against HPAF cell lines by MTS assay. The tested analog concentrations were
0.625, 1.25, 2.5, 5, 10, 20, 40 µM. The process and steps for DA-MB-231 was repeated
for this cell line also.
The data related to HPAF shown that among curcumin analogs, compound 86
shown the best anticancer activity against this cancer cell line after 72 hours. On the other
hand, triazole curcumin analogs did not show any anticancer activity against HPAF.
Like human head & neck cancer cell line, these data also might be due to the
hydrogen bond interactions between the side chain of curcumin analogs and receptors, as
well as a big molecular weight of some triazide curcumin analogs.
Analysis the anticancer activity of curcumin analogs on MG118 as human
glioblastoma cell line
Cell Titer Glo-2 assay was used for study the anticancer activity of curcumin
analogs on MG118 cancer cell lines. This assay which working based on the measurement
of ATP, determines the number of viable cells in culture by measuring ATP which
indicates the presence of metabolically active cells. The results are shown that compound
49 (IC50: 0.9 µM), 51 (IC50: 0.4 µM) which are classified in pyrazole curcumin analogs,
and 80 (IC50: 8.8 µM) as a triazole curcumin analogs showed good anticancer activity
against glioblastoma cancer cells.

CHPTER FIVE: SUMMARY, CONCLUION AND RECOMMENDATIONS
In this project, we have synthesized 14 pyrazole and triazole curcumin analogs and
characterized them by H-NMR and Mass spectroscopy. They were tested against head and
neck, human breast , pancreatic and human glioblastoma cancer cells. Pyrazole curcumin
analogs showed more anticancer activity which might be due to more hydrogen bond
interaction of side chain of pyrazole curcumin analogs with the receptor binding site. The
docking study also confirmed this interaction with compound 81 and SH domain of
STAT3.
Triazole curcumin analogs did not shown good anticancer activity might be because
of less hydrogen bond interaction with the binding site of receptor as well as the huge
molecular weight of these curcumin analogs which led to not following the Lipinski’s rule.
Since curcumin-propargyl analog was synthesized as a first step of making triazole
curcumin analogs, shown good anti-cancer activity on human breast cancer cell line (DAMB 231) and on pancreatic cancer cell line (HPAF cells) we recommend to synthesis more
curcumin-propargyl analogs and test them on various cancer cell lines. Moreover, since
curcumin-pyrazole analogs with the 6-hetrocyclic substitution contain one or two nitrogen
atom, shown good anticancer activity on head and neck cancer cell lines (CAL 27, UMSCC-74A), as well as human breast cancer cells (MDA-MB 231), pancreatic cancer cells
(HPAF) and glioblastoma (MG118), we are recommending to synthesize these kind of
analogs with one or two nitrogen in the 6-heterocylic substitution groups.
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PART TWO
DISCOVERY OF NOVEL HIT MOLECULES TARGETING CXCR4

CHAPTER ONE: INTRODUCTION
1.1

CXCR
Chemokine receptors belong to the family A of G-protein coupled receptors

(GPCRs), characterized by a seven transmembrane (7TM) helical domain (figure 2-1 1).
There are 18 human chemokine receptors that are primarily activated by different
subfamilies of chemokines: C (XCR1), CC (CCR1, CCR2, CCR3, CCR4, CCR5, CCR6,
CCR7, CCR8, CCR9, CCR10), CXC (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5,
CXCR6), or CX3C (CX3CR1), and four atypical decoy chemokine receptors (ACKRs:
ACKR1, ACKR2, ACKR3/CXCR7, and ACKR4). Chemokine receptors and ligands
interaction involves via a two-step binding mechanism[182]
(i) C-terminal region of the chemokine first binds the N-terminus region and
extracellular loops of the receptor (chemokine recognition site 1, CRS1)
(ii) N-terminus of the chemokine to target the 7TM helical bundle (chemokine
recognition site 2, CRS2) and stabilize the receptor in an active conformation that
facilitates intracellular signal transduction.
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A

B

Figure 2-1 1. Chemokine receptor. A. Three pdb structures aligned (3ODU, 3OE0
and 4RWS). B. X-RAY crystal structure of Chemokine receptor (3ODU.PDB)

CHAPTER TWO: LITERATURE REVIEW
2.1

CXCR4
The expression of CXCR4 gene leads to making a CXCR4 protein which is the

receptor protein that spans the outer membrane of cells (G-protein-coupled receptors
(GPCR)), specifically white blood cells and cells in the brain and spinal cord[183]. When
the ligand which is called SDF-1 bind to the CXCR4 receptor, it activates signaling
pathways inside the cells (figure 2-2 1 )[184]. These pathways play important roles in cell
growth, invasion, proliferation, differentiation, and cell survival. Once signaling is
stimulated, CXCR4 is internalized and broken down so it can no longer activate the
signaling pathways[185]. This receptor is also involved in the migration of cells[186]. The
high level of CXCR4 ligand (SDF-1) were observed in boon marrow cell lines which can
help certain blood cells migrate to and stay in the bone marrow until they are needed
elsewhere in the body[187]. This receptor is also involved in a number of biological
processes like invasion, proliferation and angiogenesis[188]. Research have shown that
this protein also involved in a variety of disorders like cancer and WHIM syndrome[189].
Overexpression of CXCR4 leads to the cancer metastasis due to the dysregulation of this
protein[190]. Moreover, this protein is using as prognostic marker in various cancer types
like leukemia and breast cancers which emphasize the fact that CXCR4 is an important
molecule involved in several aspects of cancer progression[191].
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A

B

Figure 2-2 1. A. Binding of (6,6-dimethyl-5,6-dihydroimidazo[2,1b][1,3]thiazol-3-yl)methyl N,N'dicyclohexyl imido thiocarbamate in the active site of
CXCR4 receptor. B. Ligand binding interactions.

2.1.1

Receptor grid generation

The structure chemokine receptor inhibitor bound complex X-ray crystal structure
(3ODU) was retrieved from the protein Data Bank. The receptor grid box was generated
by utilizing the makemyreceptor. Docking of ligand cannot be performed before the grid
generation step. Self-docking was performed to validate the receptor grid file and docking
protocol (figure 2-2 2).
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Figure 2-2 2. Receptor grid file prepared from 3ODU.PDB

CHAPTER THREE: DESIGN OF THE STUDY
3.1

Virtual screening
Analysis of co-crystallized complexes of CXCR4 inhibitors revealed the important

interactions between the protein and ligand. Based on the resolution of the X-ray crystal
structure, a pdb (3ODU) was chosen for docking studies. 3ODU is x-ray crystal structure
of CXCR4 chemokine receptor complex with the small molecule (6,6-dimethyl-5,6dihydroimidazo[2,1-b][1,3]thiazol-3-yl)methyl N,N'dicyclohexylimido thiocarbamate
(Resolution 2.50 Ao)[192]. A Natural product database from a UNPD database was
selected for the present study. Natural product database UNPD consist of 229358
molecules. Omega2 was used to generate the conformers for each compound. To exhibit
the various conformations of selected library compounds, OMEGA2[193] was employed.
It is a rapid conformer generation tool developed by OpenEye that optimizes geometry
using a modified Merck Molecular Force Field (MMFF). During the conformation
generation, the OMEGA default parameters were employed. FRED[182] docked multiple
conformers into the receptor active site. The exhaustive search method systematically
allows the rotation and translations of each conformer and the top scoring poses are
optimized and scored (figure 2-3 1).

89

90

Figure 2-3 1. Virtual screening flow chart
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3.2

Virtual Screening Hit analysis
The top scored 500 hits in each subset were visually inspected for crucial ligand-

protein interactions to pick the right compounds for further analysis.
Steps involved in the selection of final hits:
1. The crucial interaction such as hydrogen bond (HB) with Glu288 was considered.
2. The compounds with undesirable groups, bad ring geometry, duplicates were
removed.
3. The Chemguass4 score of the cognate ligand was compared with the scores
obtained for the VS hits. The hits with comparable and or even better docking scores were
selected.
4. Hits with desired molecular properties are analyzed (figure 2-3 2, 2-3 3, 2-3 4, 23 5).
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Figure 2-3 2. Hits identified from Virtual screening (UNPD12783)
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Figure 2-3 3. Hits identified from Virtual screening (UNPD102429)
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Figure 2-3 4. Hits identified from Virtual screening (UNPD20535)

95

Figure 2-3 5. Hits identified from Virtual screening (UNPD93976)
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3.3

Computational Details:
The molecular dynamics simulations were performed using Gromacs 2016.3

package[194]. The selected protein-ligand complexes were solvated in a cubic box with
dimensions of 12.4 × 12.4 × 12.4 nm. The forcefield parameters of Amber99SBILDN[195] and general amber forcefield (GAFF)[196] were used for protein and ligands,
respectively. The atomic partial charges were calculated using quantum chemical
calculations. Electrostatic potential was calculated using the B3LYP/6-31+G (d, p) level
of theory, followed by the restrained electrostatic potential (RESP) method was used[197].
The cubic box was solvated with SPC/E water models[198] and the entire system was
neutralized by adding chloride ions (Cl-). Periodic boundary conditions (PBC) were
applied for all three dimensions. The system was minimized using the steepest descent
algorithm. Then, the system was equilibrated by employing isothermal-isobaric (NPT) and
isothermal-isochoric (NVT) to maintain the temperature at 300 K and 1 bar pressure.
Parrinello-Rahman barostat and V-rescale thermostat were used to equilibrate the system
for 2 ns. The integration time step of 2 ps was used to calculate the equations of motions
by employing the Leap-frog algorithm[199]. All the bonds involving hydrogen atoms
were constrained using the LINCS algorithm[200]. The cut-off of 10 Å was used to
calculate the non-bonding interactions. Long-range electrostatic interactions were
calculated by using Particle Mesh Ewald (PME) method[201]. Finally, the production run
was performed for 50 ns. The basic analyses were performed from the Gromacs suite
programs. VMD[202] and pyMOL[203] programs were used for trajectory visualization
(figure 2-3 6).
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Figure 2-3 6. The docked conformations of chemokine receptor with four natural products.

CHAPTER FOUR: RESULT & DISCUSSION
The chemokine receptor was strongly stabilized with the presence of four natural
products. The equilibration of these complexes were confirmed by plotting the energy
terms with simulation time.

4.1

Structural stability of CXCR4 chemokine receptor:
To understand the stability of chemokine receptor complexes, we have

calculated the root mean square deviation (RMSD) and radius of gyration (Rg) of the
protein backbone. The RMSD measures the structural (conformational) changes of the
protein during the MD simulations. The Rg calculates the compactness of the protein
structures with the presence of natural products. We observed that the average RMSD
value of the chemokine-UNPD93976 complex is 10.0 Å which is a very higher value than
the other complexes. The complex of chemokine-UNPD102429 is strongly maintained
their protein backbone during the simulation. The RMSD plots of the four complexes were
shown in Figure 2-4 1. We have also calculated the Rg for the chemokine receptor
complexes. The average Rg value of UNPD93976 is 3.09 nm, which is a very lesser value
than the other complexes. The compactness of the chemokine-UNPD93976 is decreased.
The Rg plots were displayed in Figure 2-4 1.

98

99

Figure 2-4 1. The Chemokine complexes of (A) RMSD and (B) Rg plots.
The H-bonding interactions between the chemokine receptor and the selected natural
products were calculated. We observed that the chemokine-UNPD12783 complex has
more H-bonds than the other complexes. Whereas, the average H-bonding interactions of
chemokine-UNPD102429 is 0.3, which is very less. The H-bonding interactions were
displayed in Figure 2-4 2.

Figure 2-4 2. The number of H-bonding interactions between chemokine and four natural
products.

4.2

Molecular dynamic (MD)
Computational drug discovery which is an interesting technique for researchers can
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accelerate the challenging process of designing and optimizing a new drug candidate[204].
Computational structure-based drug design (SBDD) was using in the past decade due to
the rapid development of faster architectures and better algorithms for high-level
computations in a time-affordable manner[205].
Classical molecular dynamics (MD) simulations fully account for structural
flexibility of the overall drug–target model system by using SBDD strategies[206], [207].
It was accepted that Emil Fischer’s rigid lock-and-key binding paradigm are replaced by
two major drug-binding paradigms which are induced-fit and conformational
selection[208], [209],[210]. Receptor and ligand flexibility are two major factors for
correctly predicting drug binding and related thermodynamic and kinetic properties[211],
[212].
MD is using for studying the interaction and motion of atoms and molecules based
on Newton’s physics. In this technique, the force filed is using for estimating the forces
between interacting atoms and calculate the overall energy of the system. In the MD,
Newton’s laws of motions leads to the generation of successive configurations of the
evolving system, providing trajectories that specify positions and velocities of the particles
over time. Moreover, MD can calculate variety of properties like free energy, kinetics
measures, and other macroscopic quantities, which can be compared with experimental
observables. This technique was used for theoretical physics in the late 1950s, but now it
is applying in chemical physics, materials science, modeling of biomolecules, and more
recently, drug discovery[213], [214], [215].

CHAPTER FIVE: SUMMARY, CONCLUSSION AND
RECOMMENDATION
In this study, 229358 natural product compounds were screened virtually. Based on
the crystallography structure and antagonist binding site, the receptor file were generated.
FRED docking led to the identification of 500 hit compounds out of 229358 compounds.
500 hit compounds were filtered based on some parameters which led to the identification
of 4 hit molecules. Molecular dynamic analysis by Gromacs, led to the identification of 2
hit molecules for CXCR4 antagonist activity.
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APPENDIX

Figure 1. H-NMR spectrum of compound 49
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Figure 2. H-NMR spectrum of compound 50
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Figure 3. H-NMR spectrum of compound 51
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+MS2 (511.40): 0.335 to 1.725 min from Sample 1 (TuneSampleID) of MT20211112091355.wiff (Turbo ...

Max. 2.3e4 cps.
495.1

2.2e4
2.0e4
1.8e4
1.6e4

Intensity, cps

1.4e4
1.2e4
1.0e4
137.2

373.3

8000.0
511.4

6000.0

306.9

315.1

477.1

207.1

4000.0

320.4

355.1
331.2

319.4

343.1

299.3 304.4

2000.0

276.2

123.4
117.2 122.2

135.1149.3
132.1 170.5

174.2 198.7

227.4

262.3

285.4

305.9
282.4

449.2
387.2

479.3
465.4

369.3 375.1

301.1 329.2 338.8
380.0

386.4 411.4

420.7

447.3
441.9

481.5

496.8
493.9
509.4

0.0
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500
m/z, Da

Figure 4. MS spectrum of compound 51
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Figure 5. H-NMR spectrum of compound 57
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Figure 7. H-NMR spectrum of compound 58
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Figure 8. MS spectrum of compound 58
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Figure 9. H-NMR spectrum of compound 59
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Figure 10. MS spectrum of compound 59
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Figure 11. H-NMR spectrum of compound 60
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Figure 13. H-NMR spectrum of compound 65
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Figure 14. MS spectrum of compound 65
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Figure 15. H-NMR spectrum of compound 68
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Figure 17. H-NMR spectrum of compound 81
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Figure 18. H-NMR spectrum of compound 86
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Figure 19. MS spectrum of compound 77

550

600

650

700

121

+Q1 MI (1 ion): 0.031 to 1.813 min from Sample 1 (TuneSampleID) of MT20211110105032.wiff (Turbo ...

9.0e4
8.0e4
7.0e4

Intensity, cps

6.0e4
5.0e4
4.0e4
3.0e4
2.0e4
1.0e4
0.0

661.750
m/z, Da

Figure 20. MS spectrum of compound 78

Max. 9.3e4 cps.

122

+MS2 (579.60): 4.740 min from Sample 1 (TuneSampleID) of MT20211116111438.wiff (Turbo Spray)

Max. 2.1e5 cps.
579.3

2.1e5
2.0e5
1.8e5
1.6e5

Intensity, cps

1.4e5
1.2e5
1.0e5
8.0e4
6.0e4
4.0e4
2.0e4
0.0
100

150

200

250

300

350
m/z, Da

400

450
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